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Resumo 
Para milhões de mulheres grávidas em todo o mundo, o parasita Plasmodium falciparum 
representa uma das maiores ameaças que enfrentam. Infecções com este parasita 
podem resultar numa condição a que se dá o nome de Malária na Gravidez. Os efeitos da 
Malária na Gravidez podem ser sentidos pela mulher grávida ou pelo feto. Mulheres que 
experimentam a sua primeira gravidez estão em maior risco de infecção e 
consequentemente maior risco de efeitos adversos o que é ainda mais agravado se as 
mesmas estiverem infectadas com VIH. Em mulheres com mais que uma ou duas 
gravidezes, a existência de anticorpos contra um tipo de Plasmodium falciparum que 
afecta especialmente mulheres grávidas protege-as desses efeitos negativos.  
Nesta tese, eu desenvolvi um novo protocolo que permite avaliar a quantidade e função 
desses anticorpos e medi esses anticorpos em primigrávidas e secundigrávidas, num 
contexto de infecção por VIH. Isto permitiu-me descobrir que o VIH afecta a aquisição de 
anticorpos nas primigrávidas e que estes anticorpos estão associados a um aumento de 
peso dos fetos. Fui tambem capaz de demonstrar, pela primeira vez,  uma possível 
associação de IgE com a promoção da fagocitose de parasitas Plasmodium falciparum.  
Summary 
For millions of pregnant women all over the world the Plasmodium falciparum parasite 
represents one of the biggest threats they face. Infections with this parasite can result in a 
condition called Malaria in Pregnancy. The Malaria in Pregnancy effects can be felt by the 
pregnant women or by the foetus. Women in their first pregnancies are at highest risk of 
infection and as a result more prone to experience advserve effects, which can be made 
worse if they also exhibit an HIV infection. In women with already one or more 
pregnancies, the existence of antibodies against a type of Plasmodium falciparum that 
mainly infects pregnant women prtects them from Malaria in Pregnancy. 
In this thesis I have developed a new assay that allows the quantification and 
assessement of phagocytic function of antibodies agaisnt those parasites. I have 
measured these antibodies in primigravidae and secundigravidae in the context of HIV 
infection. That allowed me to find that in primigravidae HIV primarily impacts on the 
acquisition of the antibodies and that in secundigravidae these antibodies are associated 
with a higher birth weight of the babies. I also demonstrated, for the first time, a possible 
involvement of IgE in the induction of phagocytosis of Plasmodium falciparum parasites
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Coeff Linear Regression Coefficient 
CR complement receptor 
CS2VSA  Variant Surface Antigens of the parasite line CS2 
CSA Chondroitin Sulphate A  
CSPG Chondroitin sulphate proteoglycan 
CytoD Cytochalasin-D  
DBL Duffy-Binding Like 
DDT dichlorodiphenyltrichloroethane 
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Ricardo Ataíde 2011 
 
iv 
 
GFP Green fluorescent protein 
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Hb Haemoglobin 
HIV Human immunodeficiency virus  
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IL Interleukin 
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MDM monocyte-derived macrophages  
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MiP Malaria in Pregnancy 
MIP macrophage inflammatory protein 
NG Nulligravidae 
NK Natural Killer 
P. Plasmodium 
PAMP Pathogen-Associated Molecular Patterns 
PBS Phosphate Buffer Saline 
PfEMP-1 Plasmodium falciparum Erythrocyte Membrane Protein-1 
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Phago atb Phagocytic antibodies 
PM Placental Malaria 
PMA phorbol-12-myristate-13-acetate 
PPS Patient Pooled Serum 
pRBC parasitised RBC 
PRR pattern recognition receptors 
PVM Parasitophorous vacuole membrane  
RaH polyclonal rabbit anti-human RBC IgG antibody 
RBC Red Blood Cell 
RESA ring-infected erythrocyte surface antigen 
rif repetitive interspersed family 
RPMI Roswell Park Memorial Institute Medium 
RPMI-
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RT Room temperature 
SA Severe Anaemia 
SDS Sodium Dodecyl Sulphate  
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1.1. Background to the study 
For millions of people living in tropical and sub-tropical areas, and mainly children under 
the age of five years old and pregnant women (particularly women experiencing their first 
pregnancy, i.e. primigravidae), malaria is a reality that often results in adverse clinical out-
comes and even death. Although women (as do most adults in endemic areas) are able to 
develop a clinical immunity against this disease, this immunity does not seem to protect 
them once they become pregnant. This has been an observation that has puzzled malari-
alogists and immunologists for decades. The discovery of malaria-in-pregnancy (MiP) type 
parasites and specific placental receptors that enable these parasites to bind to that organ 
generated a burst of information in the last decade or so that is beginning to paint a clear-
er image of how this parasite, a protozoan of the genus Plasmodium, causes the disease 
in pregnant women. Although efforts are currently in place to develop a vaccine that could 
prevent the majority of this burden, the development of immunity against the parasite is 
still poorly understood and that impacts on the success (or lack of it) that these efforts 
have achieved. This of course takes place in areas where, together with so many other 
maladies, HIV infection is a major health concern and inevitably influences immune res-
ponses. 
1.2. Aims and scope 
The majority of efforts aiming at understanding the immune response and development of 
immunity to the malaria parasite focus on two major areas: cellular immunity and hum-
moral immunity. This thesis focuses mainly on the hummoral immunity that is developed 
against the malaria parasite by primigravidae and comprised the following general aims: 
Understand the impact of HIV on the development of immunity in primigravid 
women from a malaria endemic area according to their MiP status; 
Identify the relative importance of antibodies that contribute to the process of pha-
gocytosis in these women as compared with the total levels of antibodies; 
Evaluate the possible role of IgE as a phagocytosis mediator in primigravidae. 
In order to do this, I developed a new method of evaluating the presence of antibodies 
that contribute to the phagocytosis process in the sera of malaria exposed individuals. 
1.3. Overview and structure of the thesis 
This thesis is divided into 5 chapters and 2 appendixes. In Chapter 1 (the present chapter) 
an overview of the rationale and structure behind this work is presented. In Chapter 2 an 
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introduction to the problem that malaria poses and to its respective pathogen‟s life cycle is 
given along with a general introduction to the problem of Malaria in Pregnancy. Chapters 
3-5 present the work and results obtained for the development of the phagocytosis assay, 
the application of it to a cohort of primigravidae and secundigravidae and early work in the 
search for an evidence for IgE as an immunoglobulin that may contribute to phagocytosis 
of Plasmodium-falciparum infected red blood cells, respectively.  
Each one of those chapters is divided into Introduction, Methods, Results, Discussion and 
References. Finally, Appendix 1 includes the publications that have arisen from the work 
presented in this thesis and the work done with collaborators during the completion of this 
thesis. Appendix 2 includes a curriculum vitae at the date of publication of this thesis. 
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2. Malaria: a general introduction 
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2.1. A global problem 
Malaria is one of mankind‟s oldest known diseases. The name malaria derives from the 
Italian „Mal aria‟ which literally translates as „bad air‟, since the disease was associated 
with the bad vapours that emanated from swamps and marshes  
The agent that causes this disease is a unicellular apicomplexan parasite of the genus 
Plasmodium. There are 5 species of Plasmodium that have humans as hosts: P. falcipa-
rum, P. vivax, P. ovale, P. malariae and P. knowlesi. All of these species share common 
characteristics in their life cycles and use Anopheles mosquitoes as vectors. 
According to the World Health Organization, about 50% of the world‟s population, mainly 
in tropical and sub-tropical regions of the globe, is exposed to the disease (Figure 1). This 
resulted, in 2008, in 243 million cases of malaria worldwide and 863,000 deaths; of these 
deaths >80% occurred in sub-Saharan Africa and they were, almost exclusively, caused 
by the most virulent species of the parasite, P. falciparum [1]. 
Malaria represents not only a health problem, but it impacts greatly on the social, political 
and economic components of the endemic countries. That the countries where malaria is 
endemic and a major health issue have generally poor economies and are politically un-
stable seems no coincidence. Although major efforts have been put forward in the last 60 
years to eliminate this disease, the latest of which representing an enormous investment 
in both vaccine development and vector elimination, and until a greater international effort 
is put in place in order to increase political stability and lessen general poverty indexes in 
endemic countries, I believe Plasmodium sp. are here to stay. 
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Figure 2-1– World distribution of malaria.  
The distribution of malaria is clustered around the tropical and sub-tropical regions of the globe. As shown on 
(http://gamapserver.who.int/mapLibrary/Files/Maps/Global_Malaria_ITHRiskMap.JPG) as of November 2010. 
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2.2. The Plasmodium life cycle 
The life cycle of all Plasmodium species that infect mammals is very similar and retains 
extremely conserved morphological and developmental features (minor exceptions are the 
existence of latent parasite stages, called hypnozoites, in P. vivax and, possibly P.ovale 
[2]) ( Figure 2-2) . This complex life cycle comprises stages in a vector (mosquito) and a 
host (mammal) where 2 stages can be identified: an exo-erythrocytic stage, in the liver of 
the host, and an erythrocytic stage (blood-stage) that follows. This provides two (known) 
cell types where these parasites can replicate: nucleated hepatocytes and non-nucleated 
red blood cells. Plasmodium species that infect birds and reptiles differ in that they can 
infect and multiply in multiple tissues and cell types within their host [3, 4]. 
2.2.1. Human host 
The life cycle of Plasmodium species that infect humans begins when a female Anopheles 
mosquito, carrying Plasmodium in its salivary glands, takes a blood-meal on a human. 
Upon deposition in the skin, Plasmodium sporozoites start migrating in search for and en-
tering blood capillaries [5]. The parasites then travel to (or are most probably taken to) the 
liver where a unique combination of matrix proteoglycans seems to provide the first signal 
for their arrest [6, 7]. After their arrest, sporozoites need to find their way into the liver. 
Studies using mouse models of malaria, suggest that they use Kupffer cells (resident liver 
macrophages [8]) to do so [9, 10]. Once in the liver, sporozoites traverse several hepato-
cytes before invading and settling themselves in a final one [11, 12]. Once inside their final 
hepatocytes, sporozoites start to differentiate and eventually form merozoites. Up to 
30,000 merozoites can be generated by a single sporozoite [13]. These merozoites are 
then released from the liver and into the blood circulation through the budding of parasite-
filled vesicles called merosomes (whose membranes are of hepatic origin) [14, 15]. This is 
believed to allow the parasite‟s evasion of the host‟s immune system [16]. 
Once in the blood stream, merozoites are released from the merosomes and start invad-
ing red blood cells (RBC). This invasion process has been extensively studied and in-
volves 4 steps: (1) recognition and reversible attachment to the RBC membrane, (2) reori-
entation of the apical end of the merozoite with the RBC membrane, formation of a junc-
tion (irreversible attachment) and release of rhoptry-microneme molecules with a parasi-
tophorous vacuole membrane formation, (3) Invagination of the RBC membrane, wrap-
ping of the RBC membrane around the merozoite as there is shedding of merozoite sur-
face proteins and (4) release of the parasitophorous vacuole membrane (PVM) and its 
RBC membrane wrapping, thus completing the invasion process [13, 17-19].. Each invad-
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ing merozoite will, over a time period of 48-72h (depending on the species) generate be-
tween 16-32 new merozoites [19] which, upon release from the RBC, are able to perpetu-
ate the cycle. It is during the RBC invasion, multiplication and rupture cycle that the clini-
cal symptoms of malaria are felt [13]. Some of these merozoites, after invasion of the 
RBC, will differentiate into gametocytes [13] that can be taken-up by mosquitoes, during a 
blood-meal. 
2.2.2. The mosquito vector 
Once inside the mosquito‟s midgut, the drop in temperature and pH stimulate the male 
gametocyte to begin a process of exflagellation leading to the formation of microgametes 
that are able to fertilize the female macrogamete and originate a zygote. This zygote will 
then mature into an ookinete that penetrates the epithelial cell layer of the mosquito‟s 
midgut and forms an oocyst where consecutive rounds of division and differentiation will 
result in generation of thousands of sporozoites. These will then travel to the salivary 
glands, through the mosquito‟s haemolymph, where they will finish their maturation and be 
ready to be deposited in another human host‟s skin, when the female mosquito takes an-
other blood-meal. 
 
  
Ricardo Ataíde 2011 
 
12 
 
 Figure 2-2 - Plasmodium life cycle.  
The life cycle of Plasmodium parasites begins when an infected female Anopheles mosquito takes a blood-
meal (1). This results in the deposition of sporozoites in the skin of the human host. These sporozoites even-
tually find their way to the small capillaries that irrigate the skin and use them to reach the Liver, where they 
use Kupffer cells as their means of entry (2). Once in the Liver, the sporozoites traverse an average of 4 hepa-
tocytes before invading a final cell, where they divide into 10,000 to 30,000 merozoites (3). These are then 
released, using structures known as merosomes, into the host‟s blood-stream. Each merozoite invades a red 
blood cell (RBC) and initiates the intra-erythrocytic stage of the life-cycle. The parasites replicate asexually 
inside the RBC giving rise to new merozoites that initiate the intra-erythrocytic cycle again (4). Some parasites 
escape this cycle and mature into gametes that can be taken up by female Anopheles mosquitoes during a 
blood meal (5). Once these gametes are inside the mosquitoes‟ mid-guts they fuse and form a zygote that 
matures and invades the epithelia of the mosquitoes‟ mid-guts. Further divisions and maturation leads to the 
development of new sporozoites that migrate to the mosquitoes salivary glands, ready to be deposited in a 
new host (6).  
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2.3. Clinical features and Susceptibility to Malaria 
An infection with malaria parasites can elicit a broad spectrum of responses that range 
from no symptoms to quickly fatal disease. This is dependent on several host and parasite 
factors and on the length of exposure of one to the other [20]. In areas where there is in-
tense malaria transmission both children under 5 years old and pregnant women take the 
major bulk of the burden associated with malaria, while in areas of low malaria transmis-
sion, young adults and adults from non-endemic regions can also share the burden [1, 21, 
22]. 
2.3.1. Uncomplicated malaria 
Patients that present with uncomplicated malaria often reveal a variety of symptoms that 
overlaps that of many other diseases. These may include cough, abdominal pain, vomit-
ing, diarrhoea, headache and general body pains [20]. 
2.3.2. Complicated Malaria 
Complicated malaria includes, but is not restricted to, Cerebral Malaria (CM), defined as 
an unarousable coma that cannot be attributable to any other cause but a Plasmodium 
falciparum infection [23], severe anemia (SA), where patients present haemoglobin values 
of <7 g/dL for adults or <5 g/dL for children [23], and malaria in pregnancy (MiP).  
2.4. Malaria in Pregnancy 
2.4.1. The burden of Malaria in Pregnancy 
It has been estimated that between 25 to 50 million women/year become pregnant in ar-
eas where malaria infections are endemic, resulting in up to 200 000 infant deaths/year 
[22, 24, 25] and a very recent review increased those numbers to 125 million pregnant 
women [26]. In malaria endemic areas, pregnant women are particularly more susceptible 
to malaria infection than their non-pregnant counterparts. Women in their first (primigravi-
dae, PG) and second (secundigravidae, SG) pregnancies are the most affected suffering 
from severe anaemia and delivering low birth weight (LBW) babies [22, 27-29] although, in 
areas of low or unstable transmission CM, pulmonary oedema and renal failure may occur 
[30].  
2.4.2. The pathology of Malaria in Pregnancy 
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Most of the pathology associated with this disease is attributed to P. falciparum infections, 
although in areas where P. vivax is the prevalent species, like the Thai-Burmese border or 
regions of the Indian sub-continent, P. vivax malaria can be the causative agent of MiP 
and is associated with severe maternal anaemia, thrombocytopenia, hypoglycaemia and 
infant low birth weight (LBW) [31, 32]. In sub-Saharan Africa, where most of the samples 
used in this thesis were collected, P. falciparum infections are the most common causes 
of MiP [1]. 
The main characteristic that can be attributed to the occurrence of MiP is the presence of 
Plasmodium material in the placenta, either whole parasites (usually mature forms) or 
haemozoin [33]. This accumulation of parasite material occurs in the intervillous spaces of 
the placenta, a region where the maternal blood bathes the syncytiotrophoblast layer of 
the placenta (see Figure 2-3). Accumulation of maternal immune cells [34, 35] and an in-
creased level of inflammatory cytokines and chemokines [22, 35-38] are also associated 
with MiP particularly in PG. Several other changes can be observed in infected placentas. 
These include the excess of syncytial knotting, the thickening of the basement membrane 
of the trophoblast layer and an occurrence of excessive perivillous fibrinoid deposits [33, 
39, 40]. 
2.4.3. Plasmodium falciparum pRBC in the placenta 
2.4.3.1. The parasitized red blood cell 
Plasmodium spp. heavily modify the RBC they invade [13, 41]. As in other forms of severe 
malaria, MiP is associated with the sequestration (adhesion and immune evasion) of 
pRBC in the host tissues, in this case the maternal placenta [33]. Plasmodium falciparum 
(as do P. ovale and P. malariae) [13] pRBC possess protein structures on their surfaces 
called Knobs which seem to be associated with the capacity that these parasites have of 
sequestering in the host tissues. Knobs as observed by electron microscopy are electron-
dense, cup-shaped protrusions of the pRBC [42]. It is in this complex protein structure that 
a parasite derived protein family, Plasmodium falciparum Erythrocyte Membrane Protein 1 
(PfEMP-1), is exposed to the host and contributes to parasite sequestration by serving as 
a ligand between the pRBC and a variety of host tissues [43-46]. Besides this role in se-
questration, PfEMP-1 proteins have been linked to rosetting (a phenomenon in which 
pRBC are able to bind to uninfected RBC) [47, 48], to parasite immune evasion through 
antigenic variability [49, 50] and to the host immune response as targets of phagocytosis 
and antibody generation [51-53]. 
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PfEMP-1 proteins are encoded by a family of approximately 60 large (6-13 kb) genes 
known as var genes [45]. At any one time point, only the product of a single var gene is 
expressed on the surface of the pRBC [54] although other var genes may be simultane-
ously transcribed [55]. PfEMP-1 molecules contain cysteine-rich domains named Duffy 
Binding-Like (DBL) domains which are usually 300 amino acids long [56]. These tend to 
be interspersed by regions of highly variable sequence. There are 5 types of DBL do-
mains (alpha to epsilon) plus  
 
Figure 2-3 – Diagram of the Placenta 
A diagram of the placenta showing maternal RBC (red dots) bathing the syncytiotro-
phoblast. (adapted from [57]) 
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a more heterogeneous DBLX domain. In addition, one more domain can be identified in 
these proteins and that is the CIDR (Cysteine-rich Interdomain Region) [56]. All the mem-
bers of the PfEMP-1 family contain a transmembrane region plus a very well conserved 
intracellular region called the acidic terminal sequence (ATS). Of all the DBL domains, 
DBL1α seems to be the most conserved [58], although this only reaches 36-52% amino 
acid identity [59]. Importantly, though, var genes are able to switch and thus change the 
PfEMP-1 molecule on the surface of the pRBC allowing the parasite to exhibit antigenic 
variability [49, 60] 
Together with PfEMP-1, other parasite-derived protein families have been identified on the 
surface of the pRBC. Among these are the STEVOR and RIFIN protein families. rif (repeti-
tive interspersed family) genes form the largest Plasmodium falciparum family of multi-
genes and RIFINS can, together with PfEMP-1, be the target of an immune response by 
the host [61-63]. As for stevor (subtelomeric variable open reading frame) genes, of which 
there are approximately 30 [64], only recently have they been identified on the surface of 
pRBC as has a possible role for members of this family in the antigenic variability of 
Plasmodium falciparum [65]. 
2.4.3.2. CSA and VAR2CSA 
The binding of pRBC to the placenta of pregnant women has been one of the hallmarks of 
MiP [29, 66]. After the discovery in 1995 of the capacity of a glycosaminoglycan called 
Chondroitin Sulphate A (CSA) to serve as a receptor able to mediate the binding of pRBC, 
not long passed until it was discovered that MiP Plasmodium falciparum isolates were 
able to strongly adhere to it [67, 68].  
The involvement of PfEMP-1 in other adhesive processes, namely to Complement Recep-
tor-1 [47] and CD36 [69] made it a natural step for researchers to investigate possible 
members of the PfEMP-1 family responsible for the CSA-binding phenotype. These are 
generally referred to as Variant Surface Antigens which mediate the binding to CSA 
(VSACSA). The first candidate genes, and respective protein products, reported were 
var1csa (encoding VAR1CSA) and CS2var (encoding CS2VAR) (thoroughly reviewed in 
[70]). Both these PfEMP-1 proteins are able to bind to CSA, but it soon became clear that 
a few conditions that should be met by MiP specific VSACSA were not present in pRBC that 
expressed these proteins [70]. Namely, both var1csa and CS2var are only rarely tran-
scribed by parasites isolated from the placenta of infected women and neither of them in-
crease when laboratory parasites are selected for CSA-adherence [59, 71]. 
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Another candidate, found to be associated with the CSA-binding phenotype was the 
var2csa gene [72]. This is an unusual var gene in that it does not have a DBL1α domain 
[70]. This gene was found in isolates from infected placentas [71, 73, 74] and its expres-
sion increases with CSA-binding selection [71, 72]. Besides this, a protein associated with 
the expression of this gene, VAR2CSA, was found on the surface of pRBC and contains 
CSA-binding domains [74-78]. Serum from pregnant women from malaria endemic areas 
also proved to contain antibodies that recognised VAR2CSA showing a pregnancy-
dependent, parity dependent and sex-dependent pattern [79-85]. So far, var2csa and its 
associated PfEMP-1 protein VAR2CSA remain the best parasite-derived candidate that 
explain the higher susceptibility of pregnant woman to malaria. 
2.4.4. Immune responses to Malaria in Pregnancy 
2.4.4.1. Cellular immunity, cytokines and chemokines 
A normal pregnancy is characterised by a predominantly type-2 (Th-2) cytokine response. 
This, in contrast to the inflammatory Th-1 response, enables the mother to “tolerate” the 
foreign foetus tissues [86] and thus allows for a successful pregnancy to take place. 
MiP has been shown to be associated with a shift from the Th-2 to the Th-1 type response 
with increased levels of inflammatory cytokines and chemokines in the placenta and/or the 
periphery [36, 87, 88]. Some of these cytokines, have been shown to be associated with 
adverse outcomes like LBW (tumour necrosis factor (TNF)-α , interferon (INF)-γ) and 
anemia (TNF-α) [87, 88]. IFN-γ has also been associated with decreased prevalence of 
placental malaria, although this was done using in vitro modelling [89]. Other cytokines 
and chemokines that have been found increased in MiP (although not always associated 
with either protection from or severity of disease) include interleukin (IL)-10, IL-2, IL-8, IL-
12, macrophage inflammatory protein (MIP)-1α and MIP-1β [35, 36, 90, 91].  
Studies directed at uncovering the cells responsible for the release of these cytokines 
have revealed the possible involvement of monocytes/macrophages, NK cells and CD4-T 
cells [35, 89, 90]. This increased level of cytokines may not be just the responsibility of 
circulating immune cells, as it has been shown that the placenta itself, through the 
syncytiotrophoblast layer, is able to secrete biologically active cytokines and chemokines, 
in response to a Plasmodium infection, which in turn can attract circulating immune cells 
[92]. 
Although several studies have addressed the direct interaction of immune cells (mainly 
monocytes/macrophages and NK cells) with Plasmodium pRBC of peripheral, non-
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pregnancy related origin, no major studies have been done so far for MiP-type parasites. 
It is known that MiP-type parasites are able to evade the binding to CD36, a molecule able 
to induce phagocytosis [52, 93] but the effect of this in the activation or inactivation of 
phagocytic cells is not known.  
2.4.4.2. Humoral Immunity 
The humoral immune response to MiP (particularly in PG) will be reviewed in detail in 
Chapter 4. 
Fried et al found that the serum from Kenyan pregnant women had the ability to inhibit the 
adhesion of MiP-type parasites to CSA [94] and that it did so in a parity dependent fash-
ion, with PG failing to inhibit the adhesion of the parasites to CSA. This was the observa-
tion that demonstrated the importance of humoral immunity in MiP. Following this study, 
antibodies that are able to agglutinate placental isolates were also found in pregnant 
women [95] and a pregnancy-dependent acquisition of antibodies towards a laboratory 
adapted parasite line expressing VSACSA was described [96]. These antibodies have been 
shown to be mainly of the IgG class, with an emphasis on the IgG1 and IgG 3 sub-classes 
[97-99] which also contribute to the phagocytic clearance of pRBC [99]. 
2.4.4.3. Effectors of immunity to Malaria in Pregnancy 
Several factors have been shown to influence the development of immunity, mainly hu-
moral immunity, to MiP. Among these, environmental factors (endemicity) [100], preven-
tion strategies (use of intermittent preventive treatments) [101, 102] and HIV [80, 103, 
104] are the most important. 
2.4.4.4. Immunity towards VAR2CSA 
As was mentioned, studies have demonstrated the ability of pregnant women to develop 
antibodies that recognise VAR2CSA [79-85]. Recent studies have additionally shown the 
conservation between var2csa from geographically distant placental isolates with signifi-
cant antigenic overlap [79]. Significant epitope sharing between pregnant women‟s anti-
body responses was also observed [79]. Several domains of the VAR2CSA molecule are 
recognised by the serum of malaria exposed pregnant women, but it seems that DBL3X 
and DBL5γ are the most important targets of the immune response [76, 79-81].  
It has been shown that immune cells that contain pRBC-derived material can be found in 
the placentas of women exposed to malaria [24, 105, 106]. Nevertheless, to date no stud-
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ies have been specifically conducted with the aim of looking at VAR2CSA or its domains 
and activation of cellular immune responses. 
2.4.5. Prevention and treatment strategies for Malaria In Pregnancy 
Strategies employed for the prevention and treatment of MiP are, with few exceptions, not 
distinct from the ones used in the general prevention and treatment of malaria. Although 
not all of these strategies have been the subject of major studies directed at the specific 
effects on MiP, prevention strategies include better sanitation, insecticide spraying, use of 
bed-nets and intermittent preventive treatment during pregnancy (IPTp). Treatment of 
Plasmodium infections is highly dependent on the region and species of parasite present 
as resistance to drugs is becoming a big concern. Finally, vaccines against Plasmodium 
spp. still reveal a low level of feasibility/efficacy.  
2.4.5.1. Environmental strategies and use of insecticides 
Sanitation measures eliminate mosquito breeding sites and provide less contact between 
vector and host providing a high degree of protection, calculated at 88%, to the target 
populations [107]. The use of insecticides, both outdoors and indoors, has been the sub-
ject of long debates. Although the use of dichlorodiphenyltrichloroethane (DDT) virtually 
eliminated malaria cases in the “western world” [108] several concerns are now raised 
against its use due to environmental and health issues [109] and its proposition, by the 
WHO, for use in African countries for indoor residual spraying [110].  
2.4.5.2. Bed nets and Intermittent preventive treatment 
The use of bed-nets, and more recently, insecticide-treated bed-nets (ITN) have been 
shown to protect the target populations against malaria symptoms and adverse outcomes 
[111, 112]. 
IPTp is a strategy that consists on the receipt of drug concentrations at determined peri-
ods during pregnancy in order to maintain an adequate level of protection throughout the 
duration of the pregnancy. The drug of choice in most African countries is sulphadoxine-
pyrimethamine (SP), and despite some observed levels of resistance (and proposed 
changes in drug use [113]), SP has proved to be able to protect women from the adverse 
outcomes of MiP [112, 114-116]. 
2.4.5.3. Drugs 
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A vast number of drugs have been used with more or less success in the fight against ma-
laria in pregnancy. This has been the subject of recent reviews [117-120]. Drugs used, 
either for treatment, prophylactically or during IPTp, include Quinine (it is the oldest anti-
malarial and it appears to be safe to use for treatment during pregnancy), Chloroquine 
(more recommended to non-falciparum malarias due to P. falciparum resistance to it), 
Amodiaquine (appears safe to use), SP (first line of anti-malarials for IPTp use due to long 
half-life, presents some theoretical risks if used in the first trimester of pregnancy), Chlor-
proguanil dapsone (now withdrawn), Artemeter-lumefantrine (Coartem) and artesunate 
(not yet proven to be good pregnancy-safe drugs [121]) and Mefloquine (theoretical con-
cerns exist over its use early in pregnancy, but appears safe after that). 
2.4.5.4. Vaccines 
The development of an effective vaccine against MiP is one of, if not the major, drive be-
hind MiP research. The lack of a vaccine against not only Plasmodium spp but also any 
humanparasitic disease is an indication of the difficulty that such an endeavour repre-
sents. Although, for some, VAR2CSA represents the “golden” antigen with which vaccines 
can be developed [53], there is still a long way to go before that can be achieved. Various 
studies have shown that immunization of mice, rabbits and goats with domains of 
VAR2CSA is able to induce the production of antibodies that not only recognise the sur-
face of VSACSA-expressing pRBC but also function as inhibitors of adhesion [77, 122, 
123], but there is still some work to be done in terms of recognition of these domains by 
pregnant women‟s sera, associations of this recognition with protection from MiP, epitope 
mapping and epitope conservation between geographically distinct regions and ultimately 
clinical trials that provide hard evidence that a significant and lasting immunity can be 
achieved at low cost.  
2.4.6.  HIV and Malaria in Pregnancy 
Human immunodeficiency virus (HIV) has become over the past 30 years a major global 
health concern affecting 40 million people worldwide [124]. This virus infects cells ex-
pressing the CD4 receptor on their surfaces and integrates into the genome of the host, 
making it virtually impossible to eliminate. The interactions between HIV and malaria are 
well known, with higher rates of malaria disease and higher densities and prevalence of 
parasitaemia seen among HIV-infected patients compared to those that are uninfected 
[125-131]. On the other hand, malaria is also responsible for higher HIV-1 viral loads [132, 
133] demonstrating that both infections are able to directly affect the outcome of one an-
other.  
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2.4.6.1. Impact of HIV on immunity to Malaria in Pregnancy 
During pregnancy, HIV has profound impacts on the immunity to MiP. Studies have dem-
onstrated that HIV-positive women possess less anti-VSACSA antibodies when compared 
to HIV-negative women [103, 134], which may contribute to the increased amount of 
parasites observed in the placentas of HIV-positive women and lead to a higher impact of 
MiP. As was mentioned earlier, various cell types are able to secrete chemokines and cy-
tokines that are important effectors during MiP. HIV infections significantly reduce the pro-
duction of IFN-γ by maternal immune cells stimulated in vitro with crude malarial antigens 
[135], thus depriving the placenta of a cytokine associated with better outcomes [89]. IL-
12, a cytokine involved in the regulation of IFN-γ was also found to be reduced [136]. As 
would be expected the levels of these cytokines were highly associated with the numbers 
of CD4+ T cells [135, 136]. Although no studies have been conducted so far (representing 
a serious lack of knowledge) on the function of monocytes/macrophages in HIV/MiP co-
infected women, it is known that changes in the composition of the monocyte/macrophage 
populations do occur with an increase in CD16+ macrophages carrying HIV-1 visible in 
HIV/MiP co-infected women [137]. 
2.4.6.2. Antiretroviral drugs and Malaria in Pregnancy 
There is a striking lack of information regarding the interaction between antiretroviral 
drugs and all aspects of MiP. 
 What is known is that antiretroviral drugs are becoming widely available in more areas of 
the globe where antimalarials are also highly used. The potential for interactions between 
both treatment drugs has not been appropriately investigated and studies call for more 
information [120, 138].  
The role that antiretrovirals can play in the acquisition or maintenance of immunity against 
MiP, be it cellular or humoral immunity, has also not been the subject of many studies al-
though that promises to change in the near future. Although these studies were all per-
formed outside of the context of MiP, it is worthwhile to mention that Nathoo et al have 
looked at the CD36-depleting effect that antiretrovirals have on macrophages [139] and 
that a very exciting field of research is now beginning with the discovery of the potential 
for antiretroviral drugs to act as antimalarials [140-143]. 
2.5.  Non-falciparum Malaria during pregnancy 
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This thesis is purposely biased towards the study of Plasmodium falciparum parasites and 
pregnancy due to the low evidences, so far, for the involvement of other Plasmodium spp 
in the occurrence of MiP. Plasmodium vivax infections can result in severe anaemia and 
low birth weight during pregnancy as well as increase the risks of still births and miscar-
riages [31, 144]. Very recently, Plasmodium vivax was shown to also be able to adhere to 
placental cryo-sections, albeit at extremely low levels, but more evidence will need to be 
gathered [145]  
2.6.  Summary 
MiP remains a major health problem and presents numerous challenges that need to be 
addressed in order to improve the life of the millions of women, their offspring and ulti-
mately their communities and countries. Parasites that adhere to the placenta of the 
women affected elicit an immune response that we need to be able to accurately measure 
and understand in order to develop the best treatments and ultimately the best vaccines. 
Interactions of HIV with MiP will remain extremely important in sub-Saharan Africa and 
understanding how HIV affects the development of immunity to MiP is critical. 
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3.1. Introduction 
The measurement of antibodies towards malaria parasites (both as markers of infection 
and/or protection) has been one of the most widely used tools in malaria immunology (re-
viewed in Chapter 2). The discovery that serum antibodies raised in malaria infected pa-
tients, when incubated with parasites that were subsequently injected into a different host, 
protected this host from the infection [1] allied with the growing awareness in the 1960‟s 
[2] that anti-malarial immunoglobulins were associated with protection from disease, led to 
the development of techniques that would allow investigators to look in more detail at 
these antibodies. The methods employed for the measurement/detection of antibodies 
towards malaria have been evolving with time, following both the knowledge of the dis-
ease itself and the availability of new technologies. 
From standard microscopy, to immunoblots, to ELISAs to Flow cytometry a number of dif-
ferent methods have been employed to look at a number of antibody parameters: titre, 
class (or isotype), sub-class, function. Almost all of these methods can be grouped into 
four main categories: 
Agglutinating assays – where antibodies are measured (functionally and quantitatively) by 
their capacity to cause pRBC to agglutinate. This usually happens due to antibodies pre-
sent in the serum binding to more than one antigen, and thus causing the antigens to 
“clump together” (agglutinate). An example of an early application of this test to malaria 
can be found in [3]. 
In total binding assays, the total amount of antibodies, or an antibody class (e.g. IgG) that 
bind to a specific malarial antigen (e.g. schizont extracts, late-stage whole parasites, spe-
cific parasite proteins, etc) are evaluated, with no regards for the functionality of these an-
tibodies. ELISA and Flow cytometry based assays looking at the total IgG to pRBC Variant 
Surface Antigens (VSA) are a good example of these [4] 
In anti-adhesion assays the ability of antibodies (either present in serum or purified) that 
cover the surface of pRBC to prevent the adhesion of these pRBC to a target tis-
sue/cell/receptor is assessed. For an example of these, see [5]. 
Phagocytosis assays are assays in which the capacity of antibodies to opsonise the sur-
face of the pRBC and elicit a phagocytic response from leucocytes (either neutrophils, 
monocytes, macrophages or various cell lines) is evaluated. Although phagocytosis is 
recognisably an important immune function in malaria (particularly associated with the role 
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of the spleen in the clearance of the parasites) these antibodies haven‟t been the subject 
of many studies at the population level. For an example of one such study see [6]. 
3.1.1. Use of serology tests in malaria in pregnancy 
As reviewed by Beeson and Duffy in 2005 [7], the methods used for the analysis of anti-
malarial antibodies and their relationship with MiP, involved only three of the four above-
mentioned categories. As can be seen in Figure 3-1 – until 2005, the predominant meth-
ods used for the evaluation of antibodies in MiP were anti-adhesion assays, agglutination 
assays and particularly total IgG binding assays (with flow cytometry based assays replac-
ing old immune-fluorescence based assays). The absence of phagocytosis assays is im-
portant if we take into account the relevance that is attributed to phagocytes (from the 
Greek “phago” eat and “Cite” cell) in the spleen [8, 9]. The review by Beeson and Duffy 
only gives us the methods employed after 1998 with the discovery of antibodies to VSA 
involved in the binding to Chondroitin Sulphate A and their association with parity [5], but it 
is fair to say that even before that there were no large studies looking at the role of 
phagocytes in MiP. 
 
Figure 3-1- Antibody methods used in the detection of antibodies during MiP (adapted from [7])  
There were, evidently, studies that looked at the presence of antibodies associated with 
MiP before the 1998 date set by that review [10-19], but as far as MiP is concerned only 
after that seminal date were antibodies consistently found to be important sources of in-
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formation (thoroughly reviewed in Chapter 4). From 1998 until the time of writing of this 
thesis, 4 studies focused on phagocytosis and MiP [6, 20-22] (see section 1.5.1). 
3.1.2.  Phagocytosis  
3.1.2.1. What is phagocytosis 
Phagocytosis is a highly conserved and complex process that has evolved in eukaryotic 
cells, with the exception of yeasts, for the uptake (either for metabolic processes or for 
destruction) of particulate matter. 
Since first observed by Metchnikoff in 1905 (reviewed in [23, 24]) phagocytosis has been 
a focus of research. With roles in host defence, ingestion of metabolites, inflammation and 
tissue homeostasis, phagocytosis is mediated by receptors on the surface of cells [25]. In 
mammals, these cells can be divided into non-professional phagocytes (epithelial cells, 
fibroblasts) and professional phagocytes (neutrophils, dendritic cells, mono-
cytes/macrophages) [24, 25]. 
3.1.2.2. The mechanism and receptors involved in phagocytosis 
 Groves et al, reviewed the molecular mechanisms behind this process in 2008. In its 
classical sense, phagocytosis is a receptor mediated zipper-like process [26]. This multi-
step process initiates with the recognition of the particle either directly (by pattern recogni-
tion receptors, PRR) or indirectly (through agents called opsonins that recognise and 
cover the surface of the particle, e.g. IgG, complement). The receptors responsible for 
recognising opsonins include Fc-receptors (FcR) [27] and complement receptors (CR1-4) 
[28] while those that directly recognise the particles include a series of receptors that rec-
ognise molecular patterns previously referred to as PAMPs (Pathogen-Associated Mo-
lecular Patterns) [25]. This designation, PAMPs has been criticised as it does not include 
molecular patterns found on commensal bacteria and necrotic and apoptotic cells. A 
member of the PRR group is CD36, a glycoprotein expressed by a variety of types of cells 
[29] and known today to be an important mediator of the phagocytosis of malaria pRBC 
[30]. Other receptors of the same diverse group are able to mediate phagocytosis, as is 
the case of SR-A, but still have controversial roles during a malarial infection [31-34] 
3.1.2.3. Fc-receptors 
Most interactions between cells of the immune system and antibodies are mediated by 
glycoproteins on the surface of the immune cells called Fc-receptors (FcR). Although both 
IgA [35] and IgM [36] isotypes have their own receptors (FcαR and FcµR, respectively) 
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their role as mediators of phagocytosis is not proven, so I will focus on the FcR that rec-
ognise IgG (FcγR) and IgE (FcεR). 
The structure and homology between both FcγR and FcεR, as well as their roles as im-
mune mediators, have been thoroughly reviewed [27, 37]. Both receptor families have 
subunits derived from a common ancestral gene. FcR are designated by their affinity to-
wards the immunoglobulin isotype to which they bind. So for FcγR we can find three 
groups of receptors according to their affinity to IgG (from high to low): FcγRI (CD64), 
FcγRII (CD32) and FcγRIII (CD16) [27]; and for FcεR we find also three groups, once 
again from high to low affinity: FcεRI , FcεRII (CD23) [38] and Galactin-3 [39, 40]. Adding 
to the complexity of these receptors is the fact that CD32 has 2 isoforms that differ in their 
role. CD32a is an activating isoform that promotes phagocytosis, while CD32b is an inhibi-
tory receptor that downregulates the phagocytosis activity [37].  
It is worthwhile mentioning that, although IgG is present at much higher concentrations in 
human serum than IgE, the affinity of IgE for its high-affinity receptor FcεRI is two to five 
orders of magnitude higher than that of IgG to CD64, and that the “low-affinity” receptor 
CD23 has as much affinity for IgE as CD64 has for IgG [38] (For more on IgE view chap-
ter 5). 
3.2. Phagocytosis and Malaria 
3.2.1. The beginning 
Early on, during the course of assessing the protective effect that antibodies seemed to 
have on the protection from a malaria infection [2, 41], researchers developed two non-
conflicting theories. The first one stated that antibodies (mainly of the IgG isotype [2]) 
would block the entry of merozoites into RBC, thus preventing the infection from occur-
ring. This was supported by studies showing that serum from patients living in malaria-
endemic areas was able to inhibit in vitro cultures of Plasmodium falciparum [42-44]. The 
second theory sprang from the observation that enlarged spleens containing immune cells 
full of malaria pigment were one of the features of a malaria infection [8, 9]. The role that 
these cells, mainly monocytes/macrophages [9], could have in the clearing of malaria 
parasites was supported by several studies, both in animal models and using human-
derived cells, showing the phagocytic activity of monocytes/macrophages against malaria 
parasites and the enhancement of that activity promoted by immune sera from individuals 
from malaria-endemic countries [45-47]. 
3.2.2.  Monocytes and malaria 
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As was noted above, early observations pointed to the role that monocytes and macro-
phages, especially of splenic origin, could play in the clearance Plasmodium parasites [8, 
9]. It was also early understood that although monocytes and macrophages were able to 
phagocytose pRBC alone, their capacity to do so dramatically increased with the opsoni-
sation of the targets with immune sera [45-47].  
3.2.3.  Non-opsonic phagocytosis 
Immune cells, particularly monocytes/macrophages, dendritic cells and neutrophils are 
able to recognise particles that have not been opsonised by either complement or antibod-
ies. This is referred to as non-opsonic phagocytosis and it is mediated by receptors on the 
surface of the immune cells that recognise certain molecular patterns on the surface of 
pathogens, commensal bacteria and self-apoptotic or -necrotic cells [25]. These receptors 
include the Toll-like Receptors, Scavenger receptors (of which CD36 is a member) and 
other Pattern Recognition Receptors (e.g. the macrophage Mannose Receptor) [48]. 
TLR functions and their modulation during exposure to malaria parasites have revealed 
these receptors as an important part of the innate immune response. Of particular interest 
to malaria are TLR2 and TLR4 (capable of binding parasite-derived glycosylphosphatidy-
linositol (GPI)), and TLR9 (an intracellular receptor capable of interacting with parasite de-
rived hemozoin). These are not, however, essential for the phagocytosis of the pRBC [49-
51]. 
The CD36 receptor, an integral membrane protein of many cell types, is especially impor-
tant and has been widely studied in malaria [30, 52-59]. Not only has CD36 been shown 
to be recognised by several natural isolates of Plasmodium falciparum and to aid in the 
sequestration of this parasite in the tissues of the human host [59, 60] but also studies 
have demonstrated, both in animal models [58] and in human models [30, 57] the ability 
that macrophages have of using this receptor to phagocytose intact and unopsonised 
pRBC.  
It is interesting to point out that there is some evidence pointing to the independent path-
ways by which these two sets of receptors (TLRs and CD36) act since monocytes can 
perform CD36-mediated phagocytosis without eliciting TLR activation and, on the other 
hand, be activated by parasite-derived TLR ligands in the absence of CD36 [61]. 
3.2.4. Opsonic-phagocytosis 
As was mentioned earlier, both complement proteins and antibodies can attach to, and 
thus cover, the surface of particles (including pathogens, apoptotic cells or even healthy 
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cells in the case of immune auto-antibodies) and by doing so have the potential to induce 
the phagocytosis of these particles by monocytes/macrophages and neutrophils. The 
process of attaching to, and covering, the surface of an antigen is called opsonisation and 
so both complement and antibodies can be referred to as opsonins [48]. 
The complement system, a cascade of proteins and glycoproteins present in the serum, 
can have very diverse functions, from opsonisation of targets, to chemotaxis, to direct ly-
sis of a pathogen or even as an homeostasis regulator [48, 62]. The role of complement 
and complement receptors in inducing the phagocytosis of malaria pRBC has been the 
focus of some interesting research during the last decade. It has been shown that C3b, a 
component of the complement cascade that induces phagocytosis in macrophages [28, 
63, 64] can bind to immune complexes on the surface of pRBC and induce one of two 
functions: either stripping (a process by which the entire immune complex and associated 
receptors on the surface of the pRBC are literally stripped off by macrophages, leaving the 
pRBC surface “free” of complement receptors, like CR1) or phagocytosis [65]. C3b can 
also bind directly to antigens and stimulate its clearance by liver macrophages (Kupffer 
cells) although not all the receptors on the Kupffer cells responsible for this have been 
identified [66]. It does not seem like complement is able to directly induce the lysis of 
pRBC [67]. 
Both IgE (reviewed on Chapter 5) and IgG can opsonise and induce immune cells to re-
spond to targets. These responses can be of two sorts: Antibody Dependent Cell Cytotox-
icity (ADCC) or phagocytosis [25, 38, 61, 68-73]. In ADCC, the immune cells (monocytes, 
macrophages, mast cells, NK cells, etc) recognize the Fc‟ portion of the antibody attached 
to the antigen and release a focused array of cytokines and enzymes that lead to the 
death of the target cell [48]. The most important mechanism used by mono-
cytes/macrophages during a malaria infection, though, seems to be the phagocytosis of 
pRBC [45, 46, 73-77]. Not all the sub-classes of IgG seem to contribute to the process of 
phagocytosis. Several studies have demonstrated that the sub-classes IgG1 and IgG3 
(called cytophilic classes due to their high capacity to induce immune cells to respond) are 
the most prominent classes among individuals living in malaria endemic areas that have 
achieved partial immunity [78] and are also the sub-classes that elicit phagocytosis in 
monocytes and macrophages [20, 72, 73]. It is worthwhile to point out that the remaining 
sub-classes of IgG, IgG2 and IgG4, have been associated with protection from malaria 
symptoms and with susceptibility to it, respectively [79-81]. It is thought that these antibod-
ies, especially IgG4 might compete with the cytophilic antibodies for epitopes on the sur-
face of the pRBC. 
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I would like to point out that in this thesis, whenever phagocytosis assays were used by a 
method that does not exclusively identify IgG1 and IgG3, the antibodies responsible for 
that phagocytosis will be referred to as phagocytic antibodies. 
3.2.5.  Monocytes and phagocytosis in MiP 
The realization that pregnant women, (especially primigravidae), in malaria endemic areas 
frequently developed an accumulation of monocytes/macrophages in the placenta, and 
that these had evidences of having phagocytosed pRBC or pRBC-derived products (e.g. 
hemozoin) [82-84] prompted investigators to research on the topic of the role of phagocy-
tosis in pregnancy. 
It was soon realised that parasites that were associated with MiP were particular in that 
they did not bind to CD36 [85] but rather to placental chondroitin sulphate A (CSA) [85, 
86] and thus could potentially avoid non-opsonic phagocytosis [87]. This particular feature 
led investigators to monitor the interaction between monocytes and parasites that exhib-
ited this CSA-binding phenotype. 
Only recently have antibodies that promote the phagocytosis of CSA-binding parasites 
been a focus of research in MiP [6, 20, 21]. They have been shown to be decreased in 
HIV infected women compared to HIV uninfected women [20, 21], to correlate with levels 
of T-CD4+ cells in HIV-infected women [21], to predict, at enrolment, anaemia at delivery 
[6], to be associated with lower incidence of anaemia at delivery [21] and to be associated 
with a lower incidence of treatment failure [6]. 
3.2.6.  Evaluation of antibodies using phagocytosis assays in malaria 
Phagocytosis assays for the evaluation of the presence of phagocytic antibodies can be 
divided into different categories according to the cell-type used (neutrophils [88], mono-
cytes [22], macrophages [20], laboratory cell-lines [6, 21, 89]), to the activation state of 
those cells (activated-adherent cells [6, 20, 21], non-activated cells [88]) or to the method 
employed to quantify it (microscopy [73], colorimetric [6, 21], flow-cytometry [22, 88]) 
(note: only some examples of studies making use of the methods mentioned are given, 
but by no means is the list an exhaustive one). 
3.2.6.1. Phagocytosis assays in MiP 
As was mentioned in section 3.1.1, four studies have been conducted in the research field 
of MiP, that have made use of phagocytosis assays [6, 20-22]. Due to the limited number 
of studies an individual discussion of each assay as employed in each study follows. 
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Chronologically, the study by Keen et al [20] was the first to make use of phagocytosis 
assays in the context of MiP. In this study, both human and mouse macrophages were 
used as adherent phagocytic cells and light microscopy was used to quantify the amount 
of phagocytosis. In contrast with this rather laborious and tedious assay, Tippet et al [22] 
developed a phagocytosis assay that was able to use both cell-lines (the Thp-1 cell line 
was used) and whole-blood and that made use of flow-cytometry to measure phagocyto-
sis. This assay still didn‟t lend itself for use with many samples, but had the great advan-
tage of allowing the use of whole-blood, and thus evaluate monocytic function in their 
“natural” environment. The next two studies, from Feng et al [6] and Jaworowski et al [21], 
both made use of a colourimetric assay using the pro-monocytic cell line Thp-1. In this as-
say Thp-1 cells are plated and stimulated with PMA (phorbol-12-myristate-13-acetate) to 
differentiate chemically for 3 days. After phagocytosis of pRBC, the Thp-1 are lysed and 
the haemoglobin released is measured using spectrophotometry. The advantage of this 
assay is that it lends itself to be used in 96-well plates and not 5-mL glass tubes (as is the 
case for Tippet et al [22]). On the other hand it relies on chemically differentiated cells and 
takes 3 days. 
3.3.  Thp-1 cells 
Thp-1 cells are a human pro-monocytic leukaemia cell line derived from a one year old 
boy with acute monocytic leukemia [90]. The first papers that described this cell line [90-
93] were able to show that they were positive for alpha-naphtyl butyrate esterase and 
negative to alkaline phosphatise and peroxidase. Examination of their karyotype revealed 
that these cells have a diploid (46) number of chromosomes. These initial studies also 
show for the first time the ability that Thp-1 cells have of ingesting IgG-covered particles, 
that this activity peaks at around 30 min and that phagocytosis is much higher for IgG-
covered particles than for non-Ig-covered particles. The ability of these cells to differenti-
ate into a more macrophage-like adherent phenotype was also evaluated and several in-
ducers of differentiation can be used (IFN-γ, Vitamin-D3, 12-O-tetradecanoylphorbol-13-
acetate (TPA), PMA) [91-95]. 
It is important to state, at this point, that from this point forward Thp-1 that are in suspen-
sion and have not been exposed to differentiating agents will be referred to as undifferen-
tiated Thp-1 (uThp-1) while Thp-1 cells that have been exposed to such agents will be re-
ferred to as differentiated Thp-1 (dThp-1). 
The differences between uThp-1 and dThp-1 have been the subject of many studies. Of 
importance for the present work is the fact that dThp-1 cells are adherent, express CD36 
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on their surface and also express CD16, all contrary to what is seen on uThp-1 cells [29, 
91, 92, 96]. 
Another, and very important, discovery was the presence of both sets of FcR (FcγR and 
FcεR) on the surface of Thp-1 cells, although CD16 is absent from uThp-1 cells [73, 94, 
97, 98] 
3.3.1.  Thp-1 and Malaria 
The first use of Thp-1 cells in malaria studies, that acknowledged the importance that 
these cells could have in the study of malaria immunity was performed by Kumaratilake et 
al in 1997 [89] using dThp-1. Tebo et al[73], in 2002, made use of dThp-1, also, and dem-
onstrated that FcγR-mediated phagocytosis could be measured by using these cells. More 
important was the fact that they used specific blocking antibodies for CD64 and CD32 and 
showed an equal contribution of both sets of receptors for the phagocytosis performed by 
these cells.. In a paper by Shwenk et al, 2003 they show that dThp-1 cells recognise and 
phagocytose sporozoites opsonised with antibody generated by an immune response to 
the central region of CS (using the RTS,S vaccine). This showed also the potential of 
these cells to be used readily as tools for vaccine development to the exo-erythrocytic 
stages of the parasite [99]. Craig et al [63], used dThp-1 to show a process called transfer, 
that basically is the “stripping” of immune complexes (IC) from the surface of pRBC and 
that is known to occur both in vivo and in vitro. Following this, came the MiP phagocytosis 
studies already discussed in section 1.5.1 [6, 21, 22, 73]. 
3.4.  Rationale for developing a new phagocytosis assay 
Thp-1 cells had already been used to measure phagocytosis of pRBC using immune sera 
[73] and had been used also to measure the levels of phagocytic antibodies in small co-
horts of pregnant women[6, 21]. None of these assays, though, had the ability to combine 
the high-throughput, reliability and reproducibility needed to conduct studies using hun-
dreds of samples. With this in mind I decided that by culturing uThp-1 cells in suspension, 
performing the assays in 96-well plates and measuring phagocytosis by Flow-cytometry, I 
could develop a more high-throughput, less user-dependent assay.  
3.5.  Methods 
3.5.1.  Cell Cultures 
3.5.1.1. Plasmodium falciparum  
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A number of different P. falciparum lines adapted for laboratory culture were used. The 
parasite lines used were the CS2 (known to bind to CSA and an accepted model of MiP 
parasites [86, 100]), a CS2 transfected with a plasmid containing a green fluorescent pro-
tein (GFP) expression cassette (kindly provided by Danny Wilson and James Beeson, 
WEHI) [101], the CS2 parental line E8B-ICAM (selected for its high binding to ICAM-1 and 
not CSA [102]) and a genetically distinct parasite line, 3D7, known to be a CD36-binding 
line, which is the most common parasite phenotype found in non-pregnant individuals 
[102].  
3.5.1.1.1. Culture of Plasmodium falciparum  
All parasite lines were cultured according to the method of Trager and Jansen [103], with 
slight modifications. The culture medium used was RPMI-2-N-hydroxyethylpiperazin-N-2-
ethane sulphonic acid (RPMI-HEPES) supplemented with 0.2% w/vol NaHCO3. CS2 and 
CS2-GFP were further supplemented with 0.5% Albumax II (GIBCOTM) while E8B-ICAM 
and 3D7 received 0.25% Albumax II (GIBCOTM) and 5% vol/vol of pooled human sera (gift 
from the Australian Red Cross Blood Service). The GFP expression plasmid of CS2-GFP 
was maintained episomally by the addition of 4μg/ml of Blasticidin-S-HCL (Invitrogen) to 
the culture medium and GFP expression was confirmed by staining pRBC cultures with 
10µg/mL of Ethidium Bromide (EtBr, Bio-Rad Laboratories) for 15 min at room tempera-
ture and comparing EtBr fluorescence in the FL-2 channel with that of GFP in the FL-1 
channel using a FACSCalibur flow cytometer (BD Biosciences). All parasite lines were 
maintained at 37°C in a low oxygen atmosphere composed of 1% O2, 5% CO2 and 94% 
N2. Type O human RBC (provided by the Australian Red Cross Blood Service) were used 
in all cultures. All parasites were selected for the expression of Knobs by gelatine flotation 
(5.1.1.4) every 2 weeks and synchronised when needed by the use of Sorbitol (5.1.1.3). 
Parasitaemia was checked by the use of thin blood smears (5.1.1.2). 
3.5.1.1.2. Monitoring cultures by thin blood smears – Giemsa Staining 
Both the stage and the parasitaemia of P. falciparum cultures were monitored using thin 
blood smears stained with Giemsa stain, as previously described [104]. Briefly, a drop of 
parasite culture was dropped onto a glass slide and smeared along it. After allowing it to 
air-dry, the slide was placed in absolute methanol for 30s and stained in 10% Giemsa 
stain in tap-water for a minimum of 5-10 min. The slides were then air dried and viewed 
under a light microscope with the help of immersion oil and a 100x objective. Parasitaemia 
was calculated by counting the percentage of pRBC relative to total RBC present in ten 
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microscope fields. All the different blood-stages of the parasite are able to be observed 
using this technique. 
3.5.1.1.3. Synchronising Plasmodium falciparum cultures – the Sorbitol Tech-
nique 
The synchronisation of parasite cultures with Sorbitol by the method of Lambros and Van-
derberg [105] (used here with slight modifications) allows us to highly enrich the parasites 
in one specific stage of their cycle (in this case, early rings). Briefly, parasite cultures ex-
hibiting early-ring stages were centrifuged at 400xg and resuspended in a 5% w/vol solu-
tion of D-Sorbitol in water at 10% hematocrit at 37°C for 5 min. The suspension was then 
centrifuged again and washed with RPMI-HEPES before being put back in culture. This 
culture would consist of RBC and early-ring stage pRBC only. 
3.5.1.1.4. Selecting Plasmodium falciparum cultures for knobs – The Gelatin flo-
tation technique 
The enrichment of parasite cultures for those parasites expressing knobs at their surface 
was done, with slight modifications, according to the method described by Goodyer et al 
[106]. Briefly, parasite cultures exhibiting mid-to late trophozoite stages were centrifuged 
at 400xg and resuspended in a 0.75% w/vol solution of gelatin in RPMI-HEPES at 10% 
hematocrit. The cells were left in suspension for 45 min in a low oxygen atmosphere com-
posed of 1% O2, 5% CO2 and 94% N2 resulting in a pellet of RBC and pRBC (rings and 
knobless mature stages) and in a supernatant of knob-expressing pRBC. This super-
natant (usually the top 2/3 of it) were then collected and washed twice with RPMI-HEPES 
before being put back into culture with fresh RBC. 
3.5.1.1.5. Purifying trophozoite stages of Plasmodium falciparum  The Percoll 
gradient technique 
Parasite trophozoites, for use in the phagocytosis assays, were purified from parasite cul-
tures using the Percoll method as described [107], with minor modifications. Briefly, para-
site cultures were overlaid on a gradient of 80%, 60% and 40% Percoll (Amersham) in 
RPMI-HEPES. After centrifugation at 2,000g x 15 min, cells resting on the 60% layer were 
collected and washed thrice at RT with RPMI-HEPES (400g for 3 min). After this the cells 
were resuspended in the appropriate volume of Thp-1 culture medium until exposed to the 
Thp-1 cells for phagocytosis. 
3.5.1.2. Culture of Thp-1 cells 
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Thp-1 cells were maintained in an humidified 37°C incubator with 5% CO2 in RPMI 1640 
(GIBCO) supplemented  with 10% heat-inactivated Foetal Bovine Serum (FBS, GIBCO), 
1% penicillin-streptomycin (GIBCO), 2 mM Glutamine (GIBCO), 25mM HEPES (GIBCO) 
and 55x10-3 mM 2-Mercapto-Ethanol (SIGMA) at a density below 5x105 cells/mL. Thp-1 
cells were obtained from the ATCC (catalog number: TIB-202™). Undifferentiated Thp-1 
cells used in our assays had not been exposed to agents such as PMA or TPA (12-O-
tetradecanoylphorbol-13-acetate) [92, 93]. 
3.5.2.  The phagocytosis assay 
3.5.2.1. A standard phagocytosis assay using uThp-1 cells and CS2-GFP para-
sites 
Mid- to late-trophozoite stage CS2-GFP pRBC (for other parasites, stained with Ethidium 
Bromide, see below) were purified by density gradient centrifugation, as described in sec-
tion (5.1.1.5). Cells were then resuspended at 5x107 cells/mL and incubated with defined 
amounts of either purified antibodies or serum, according to the test to be performed (see 
below). Typically, in a 96-well u-bottom plate previously coated with FBS, 3.3µL of serum 
samples and either dilutions of a standard patient pooled serum (pps) or of a polyclonal 
rabbit anti-human RBC IgG antibody (Abcam) (for use as a standard curve) were incu-
bated with 30µL of pRBC suspension and mixed. This included one well with no serum 
sample (no-serum control) and one well with no parasite (Thp-1 alone control). pRBC 
were opsonised by the serum for 1h at RT in the dark and resuspended once, within that 
hour. The cells were then washed thrice as before and resuspended in 150µL of Thp-1 
medium. Following this 50µL were aliquoted into three wells of a final 96-well u-bottom 
plate.  
While the pRBC were being opsonised, Thp-1 cells were collected, centrifuged at 300g for 
5 min at RT and resuspended at 5x105/mL in Thp-1 medium. 
One hundred microliters of the Thp-1 suspension were dispensed into each well of the 
final plates which contained 50 µL pRBC suspension. The cells were mixed and left to 
phagocytose for 40 min at 37°C in a 5% CO2 humidified incubator. Phagocytosis was 
stopped by centrifugation at 4°C, 350 g for 3min. The supernatant was discarded and the 
cells were resuspended at 37°C in 150 µL of FACS Lysing solution (BD Biosciences) at a 
1/10 dilution in distilled water, and left at RT for 10 min in order to eliminate unphagocyto-
sed pRBC. Lysis was stopped by the addition of 50 µL of cold PBS (-Ca2+, -Mg2+) 2% FBS 
and 0.02% NaNO3 (FACS Buffer). The plates were centrifuged at 4°C, 350 g x 3 min. After 
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3 washes with 150 µL of cold FACS Buffer at 4°C, 350 g x 3 min, the cells were fixed in 
cold 2% Paraformaldehyde in PBS and left on ice before acquiring. 
3.5.2.1.1. Flow-cytometry 
Cells were acquired in a FACSCalibur flow cytometer. Thp-1 cells alone were first gated 
on the basis of their forward- and side-scatter properties. Their level of auto-fluorescence 
in the FL-1 channel (for CS2-GFP parasites) was set to always be less than 5% (for the 
procedure when using EtBr stained parasites, see below). Sample triplicates were then 
acquired, usually at a rate of 250-350 cells/s until 10,000 Thp-1 cells were acquired. 
3.5.2.1.2. Analysis of the results 
All results were analysed using BD CellQuestTM software version 5.2.1. Triplicate results 
for samples and standard curves were obtained after subtraction of the “Thp-1 alone” re-
sults. Using GraphPad Prism version 4.2 for Windows (GraphPad Software, San Diego 
California USA), the means of the triplicate standard curve phagocytosis results were plot-
ted against their dilution. The result was a saturation curve. After natural log transforma-
tion of the x-axis, a standard curve was obtained. Samples were then transformed in the 
same way, plotted on the standard curve and transformed back in order to obtain their 
relative titre.  
Two parameters were obtained when using this assay (Figure 3-2): 
1. The phagocytic antibodies‟ function, measuring the percentage of Thp-1 cells that 
phagocytosed pRBC compared to the maximum percentage obtained in the standard 
curve (e.g. a result of 30% Thp-1 cells positive on a sample compared to 60% Thp-1 cells 
positive using positive control serum would give a 50% phagocytic activity); 
2. The phagocytic antibodies‟ titre, which, like an ELISA, compares the test sample to the 
standard curve of the positive control to derive a relative titre of antibody.  
Phagocytosis results higher than the standard curve, by the nature of the assay, were dis-
carded from the analysis. 
3.5.2.2. A standard phagocytosis assay using uThp-1 cells and Ethidium Bro-
mide-stained parasites 
Not all parasites used in this study had the advantage of having been transfected with 
GFP. Ethidium Bromide (EtBr) is a DNA intercalating dye that is commonly used for the 
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separation (in a flow cytometer) of pRBC populations from uRBC [100, 108]. This dye fluo-
resces highly on the FL2 and FL3 channels.  
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Figure 3-2 – Diagram of the parameters function and titre obtained with the uThp-1 assay 
Typical standard curve plot of percentage of patient pooled serum (PPS) used for pRBC opsonisation against 
percent of GFP-positive uThp-1 cells acquired by FACS. Indications of absolute phagocytosis values used for 
phagocytic antibodies‟ function, titre and both the titre range obtained in the study conducted on Chapter 4 of 
this thesis (PTR) and a theoretical titre range (TTR) (extrapolated from the patient pooled serum titre) are 
given. 
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All the steps for the phagocytosis assay using EtBr stained pRBC are the same as men-
tioned in section (5.2.1) with the following exceptions: 
Before opsonisation with the serum or control antibodies the purified pRBC are stained 
with EtBr. This was done by resuspending the purified pRBC at a density of 1-3x107 in a 
RPMI-HEPES solution containing 10 µg/mL of EtBr. This was followed by 15 min incuba-
tion in the dark at RT and 3 washes with RPMI-HEPES.  
Due to the nature of the dye, uThp-1 alone (no contact with parasite) will always have a 
much lower MFI than any of the other Thp-1 which contacted EtBr-stained parasites. This 
means that the proper control for this should be uninfected RBC subjected to the same 
EtBr staining process (and thus giving us an idea of the amount of “free” EtBr in the solu-
tion and that has been taken up by the uThp-1) or the use of the non-opsonised pRBC 
control to set the minimum amount for phagocytosis (see results section for a rationale for 
this). 
3.5.2.3. Phagocytosis assay using human CD14+ monocytes 
3.5.2.3.1. Isolation of CD14+ cells 
CD14 cells for use in phagocytosis assays were isolated from Buffy coats (BC) provided 
by the Australian Red Cross Blood Bank.  
2:1 volume of room temperature PBS without Ca2+ and Mg2+ (PBS-) was added to the BC. 
After calculating 5 mL of Ficoll-Hypaque to each 10 mL of BC/PBS mixture, the volume 
calculated of Ficoll-Hypaque (15 mL) was added to new 50 mL centrifuge tubes. An over-
lay, of the corresponding volume of BC/PBS mixture (30 mL) was done. Tubes were cen-
trifuged 30 min 900xg at 18º-20ºC without brake. Using a sterile transfer pipette all but 5 
mL of supernatant were removed, and kept in a separate 50 mL tube. The remaining 5 mL 
were vaccum aspirated, thus removing the upper layer containing mostly of the platelets. 
This was discarded. 
Using a sterile transfer pipette the cloudy interface (PBMCs) was removed and placed in 
new 50-mL centrifuge tubes. This was followed by a wash by adding 3x volume of PBS- 
and centrifuging 15‟ at 500xg, 18º-20ºC. After tipping off the supernatant, a new wash was 
done with chilled PBS- and centrifuging at 4 ºC. (This discarded most platelets and re-
maining Ficoll). Five mL of sterile NaCl 0.2% were addded. After 3 min 20 mL of chilled 
PBS- with 2mM EDTA (PBS-E) were added and the wash repeated. Cells were resus-
pended in 20 mL chilled PBS-E and counted using 100x dilution in Trypan-blue (0.04%). 
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After this the cells were passed through a filter before starting MACS procedure so as to 
avoid cell aggregates. 
 The isolation of specific cells populations was achieved by resuspending the cell pellet in 
80μL MACS-Buffer: PBS- with 0,5% FBS and 2mM EDTA  (MB) per 107 PBMC. After, 
20μL of CD14 MicroBeads per 107 total cells were added, mixed well and incubated for 15 
min at 4-8 ºC. Cells were then washed by adding 2 mL of buffer per 107 cells and centri-
fuging at 300xg for 10 min. The supernatant was discarded completely and the cells re-
suspended, up to 108 cells, in 500 μL of MB. 
A separation column was then placed in the magnetic field of a suitable MACS Separator 
(I have used LS columns). The preparation of the column involves rinsing with 3 mL of MB 
to extract bubbles. The cell suspension was then applied onto the column and the unla-
beled cells which pass through were collected, and the column washed with 3x3 mL of MB 
with every wash flow-through collected. This constituted the CD14neg cell population. 
 The column was then removed from the separator and placed onto a suitable collection 
tube. Five mL of MB were then applied into the column and immediately flushed out. The  
fraction with the magnetically labelled cells is dislodged by firmly applying the plunger 
supplied with the column. This constituted the CD14pos population.  
 The cells were then counted and frozen in 10%DMSO, 90% FBS (filter Sterile) 
3.5.2.3.2. The new phagocytosis assay adapted to CD14+ cells 
For the use of CD14+ cells, the new phagocytosis assay is performed as described in sec-
tion 3.5.2.1 with the following modifications: 
 The assay should start by the isolation of CD14+cells. These are plated at 5x104 
cells/well in Thp-1 medium in 96-well U-bottom plates coated with FBS and left to „rest‟ for 
1h-2h before the assay is performed. This is done to ensure that cells will not be used un-
der stress from the isolation procedure and that during the „resting‟ period the cells remain 
in suspension and do not begin attachment to the well wall. 
3.5.2.4. Minute-by-minute time course of phagocytosis 
This was performed in exactly the same way as a regular CS2-GFP phagocytosis assay, 
but after bringing together the Thp-1 cells and the pRBC, the plate was left at room tem-
perature and the cells were analysed in the FACSCalibur machine without prior lysis of 
unphagocytosed RBC or fixation. 
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3.5.2.5. The use of Inhibitors of phagocytosis 
In this work two inhibitors of phagocytosis were used.  
Cytochalasin-D (C8273, SIGMA) is a potent inhibitor of actin polymerazation and thus 
known to affect active processes like phagocytosis. One milligram of Cytochalasin-D was 
received, and diluted in 100 µL of DMSO, after which 900 µL of PBS. This resulted in a 
100x stock solution that was added to Thp-1 cells one hour before the phagocytosis.  
FcR blocking agent (Miltenyi Biotec) consists of the Fc‟ portions of human IgG antibodies 
and efficiently blocks any FcγR induced phagocytosis. This was added to the Thp-1 cells 
5 min before the phagocytosis at a 1/40 dilution from the original stock. 
3.5.3.  Human serum samples used in this chapter 
All the samples used in this study derived from studies conducted in Malawi with pregnant 
women, specifically women enrolled in the UNC and LAIS study cohorts, which have been 
described already [6, 109]. Both Gaoqian Feng‟s and Elizabeth H. Aitken‟s work was re-
analysed by me in order to get comparisons between their results and those of my assay 
and I am very grateful to them for agreeing to give me their results. 
Ethical clearance for the UNC study was provided by the College of Medicine Research 
Ethics Committee, University of Malawi and the Human Research Ethics Committee of 
Melbourne Health, and ethical clearance for the LAIS study was provided by the College 
of Medicine Research Ethics Committee and the human research ethics committee of the 
Walter and Eliza Hall Institute, Melbourne. 
3.6.  Results 
3.6.1.  uThp-1 are able to perform phagocytosis of serum-opsonised pRBC 
In order to make use of uThp-1 cells as phagocytic cells it was first required to show that 
these cells were able to perform phagocytosis of Plasmodium falciparum infected RBC.  
Using CS2-GFP pRBC opsonised with PPS or non-opsonised I was able to show that 
over 90 minutes uThp-1 could perform phagocytosis and that this phagocytosis could be 
measured by FACS (Figure 3-3). Early attempts at demonstrating that this phagocytosis 
was Fc-receptor mediated, using Cytochalasin D showed that Cytochalasin D was not 
able to completely inhibit the phagocytosis of PPS-opsonised pRBC (Figure 3-3). 
3.6.2.  Time course of phagocytosis using uThp-1 cells 
Ricardo Ataíde 2011 
 
58 
 
In order to verify what would be the minimum amount of time required for uThp-1 cells to 
perform phagocytosis of opsonised pRBC, a time-course of phagocytosis was performed. 
Four time points were chosen: 15 min, 45 min, 70 min and 90 min, using PPS opsonised 
CS2-GFP pRBC (Figure 3-4A). The results showed that 40 min was a good time to obtain 
maximum phagocytosis.  
In order to understand the kinetics of the process, a minute by minute phagocytosis assay 
was also performed, showing that phagocytosis is likely to start occurring after 10 min of 
contact between uThp-1 cells and opsonised pRBC (Figure 3-4B). 
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Figure 3-3 – First results obtained using a FACS-based phagocytosis assay with uThp-1 cells 
Two examples of results obtained with an earlier version of the phagocytosis assay are plotted. The assay 
was performed by the method described in section 3.5.2.1 with the following modifications: phagocytosis oc-
curred over 90 minutes and a 3% solution of NaCl applied for 3 min replaced FACS Lysing Solution as the 
lysing agent. (Unop) unopsonised CS2-GFP pRBC, (PPS) CS2-GFP pRBC opsonised for 1h with patient pool 
serum with known high reactivity to VSACSA, (PPS + CytoD) same as PPS except uThp-1 were exposed to 
1µ/mL of Cytochalasin D for 1h before phagocytosis. 
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Figure 3-4- Time-course of phagocytosis by uThp-1 cells 
The phagocytosis of CS2-GFP pRBC opsonised with PPS was evaluated using FACS over 4 different time 
periods (A) and in a minute by minute assay (B) in order to understand the kinetics of phagocytosis and 
choose the best time point to ensure maximum phagocytosis. Graphs represent examples of at least 2 ex-
periments. 
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3.6.3.  uThp-1 are able to detect different amounts of opsonising antibody 
When analysing the levels of antibodies present in the sera samples to be tested it is im-
portant that assays are able to detected differences in the amount of antibody present.  
CS2-GFP pRBC were exposed to different concentrations of human sera with known high 
amounts of IgG to CS2VSA. These were then mixed with uThp-1 cells for 40 min and 
phagocytosis was measured by FACS. Undifferentiated Thp-1 were able to detect differ-
ent amounts of opsonising antibody and did so in a manner that was consistent, providing 
the possibility of using standard curves to standardise assays (Figure 3-5A and 5B). Con-
sistency of results between different assays, on different days was high: intra-assay vari-
ability was minimal, with linear correlation between triplicates of serum samples run in the 
same day always high (r2> 0.98) (Figure 3-5C and 5D). 
3.6.4.  uThp-1 do not phagocytose unopsonised pRBC and seem to mainly per-
form Fc-receptor mediated phagocytosis 
Several Plasmodium falciparum parasite lines were used to assess the ability that uThp-1 
might have of performing non Fc-mediated phagocytosis. The parasite line E8B-ICAM (se-
lected for its binding capability to Intercellular adhesion molecule 1 (ICAM-1)) and the 
parasite line 3D7 (know to bind to CD36) were exposed to uThp-1 cells. Positive controls 
were, in both cases, pRBC opsonised with a polyclonal Rabbit anti-human RBC antibody. 
Inhibiting phagocytosis of IgG-opsonised pRBC, by inhibiting the process (using Cyto-
chalasin D) or the receptors (using Fc-Block) revealed that uThp-1 cells are semi-
refractory to inhibition by Cytochalasin D, since a certain degree of phagocytosis was still 
observed (Figure 3-3 – First results obtained using a FACS-based phagocytosis assay 
with uThp-1 cellsand Figure 3-7 – Phagocytosis by uThp-1 cells seems to be Fc-receptor 
dependent). When Fc-Block was used, phagocytosis was completely abrogated (Figure 
3-7 – Phagocytosis by uThp-1 cells seems to be Fc-receptor dependent).  
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Figure 3-5 – Phagocytosis by uThp-1 using CS2-GFP pRBC: titration of PPS and correlation between 
intra and inter assays 
uThp-1 cells are able to detect different amounts of opsonising antibody on CS2-GFP pRBC. (A) A typical 
example of several experiments using titrations of PPS opsonised CS2-GFP pRBC is shown. (B) After loga-
rithmic transformation the results can be expressed as a standard curve. Best-fit curve and 95% confidence 
intervals are plotted (r
2
= 0.98). (C) The analysis of several standard curves reveals the similarity of the expo-
nential phase between assays performed on different days. (D) Intra assay variability is practically negligible 
as reveals the analysis of triplicates of a typical experiment using human serum samples for opsonisation of 
CS2-GFP pRBC (in C and D, the phagocytosis is expressed as the percentage of phagocytosis obtained with 
the lowest dilution of each standard curve). (PPS) patient pooled serum. 
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Figure 3-6 – uThp-1 cells do not phagocytose unopsonised pRBC  
(A) Flow cytometry analysis of CD36 expression on thp-1 cells showing that uThp-1 cells (untreated) do not 
express the scavenger receptor CD36, contrary to dThp-1 (PMA) (figure adapted from [29]. Y-axis: number of 
cells, X-axis: Mean fluorescence intensity). uThp-1 were mainly restricted to phagocytosis of antibody opson-
ised pRBC failing to phagocytose both (B) unopsonised 3D7 pRBC and (C) E8B-ICAM parasites. Phagocyto-
sis was performed using EtBr-stained pRBC. (R-aH) Rabbit anti-human RBC antibody opsonised pRBC, 
(unop) unopsonised pRBC. Assays were done in triplicate. 
 
Figure 3-7 – Phagocytosis by uThp-1 cells seems to be Fc-receptor dependent 
 Phagocytosis of CS2-GFP pRBC either unopsonised (white) or opsonised with Rabbit anti-human RBC anti-
body (RaH) (grey). uThp-1 were left to phagocytose either alone (white and dark grey bars) or in the presence 
of phagocytosis inhibitors (light grey bars). Cytochalasin D (cytoD) was added to uThp-1 cells 1h before the 
assay. Fc-receptor blocking agent (FcBlock) was added 5 min before the assay. See 3.5.2.5.  
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3.6.5.  Phagocytosis by uThp-1 cells does not correlate completely with phago-
cytosis by dThp-1 cells  
In order to see how the new phagocytosis assay using uThp-1 assay correlated with the 
assay that was more commonly performed, using PMA-differentiated Thp-1 cells, I used a 
few samples from a study cohort that had been studied by Feng, et al using the dThp-1 
assay [6]. The results obtained with the new assay were not correlated with those ob-
tained obtained using the dThp-1 method,(Spearman‟s rank (rho= 32, P=0.231), linear 
regression (r2= 0.06, P=0.383) (Figure 3-8A)). The results were better correlated with the 
ones obtained by the use of donor monocyte-derived macrophages (MDM) also used in 
the same study (Spearman‟s rank (rho= 79), linear regression (r2= 66.8) (Figure 3-8B)). It 
should be noted that these results were obtained with a small number of samples (n=16). 
3.6.6.  uThp-1 are a feasible way of detecting patterns of hummoral response to 
pRBC VSACSA 
When applied to a larger number of serum samples from pregnant women (n=141), the 
new uThp-1 assay was able to retrieve important and coherent results. As would be ex-
pected from known patterns of immunity to pRBC VSACSA, the new assay was able to 
show the gravidity dependence of antibody production (Figure 3-9A), the decrease in anti-
body levels associated with HIV infection (Mann-Whitney ranksum: z= -3.12, P=0.002, 
Figure 3-9B) and the association of antibody levels with anaemia (Mann-Whitney rank-
sum: z= -2.0, P=0.045, Figure 3-9C), all of which published by Feng, et al using the dThp-
1 phagocytosis assay [6].  
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Figure 3-8 – Correlation of new uThp-1 phagocytosis assay with those using dThp-1 cells and MDM 
(using results obtained by Feng, et al [6]) 
The new uThp-1 assay was applied to 16 random samples from a cohort of pregnant women being studied by 
Feng, et al [6]. (A) Results obtained with the new uThp-1 assay, in this set of samples had little correlation to 
those obtained using dThp-1 cells, Spearman‟s rank (rho= 32), Linear regression (r
2
= 0.06). (B) Results ob-
tained with the new uThp-1 assay correlated with those obtained using MDM, Spearman‟s rank (rho= 79), 
Linear regression (r
2
= 66.8). For a detailed description of the dThp-1 and MDM assays refer to the reference 
given above. Each point represents the mean of duplicates. 
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Figure 3-9 – Applying the uThp-1 phagocytosis assay to large study cohorts 
The new uThp-1 phagocytosis assay was applied to a cohort of pregnant women for whom studies were al-
ready being conducted (see [6]) in order to verify the capability of the assay of detecting clinically relevant 
information. (A) The percentage of uThp-1 cells that had phagocytosed CS2-GFP pRBC opsonised with dif-
ferent patient samples correlated well with the gravidity status of the women. Mann-Whitney ranksum tests 
detected significant differences between PG and SG (** P<0.01) and between PG and MG (*** P<0.001). (B) 
Phagocytosis of CS2-GFP pRBC opsonised with patient serum samples by uThp-1 cells was able to detect a 
decrease in the levels of phagocytic antibodies in HIV positive women when compared to HIV negative 
women. P-value for Mann-Whitney ranksum is shown. (C) Phagocytosis of CS2-GFP pRBC opsonised with 
patient serum samples by uThp-1 cells was able to detect an association between phagocytic antibodies at 
time of enrolment and maternal anaemia status at delivery. P-value for Mann-Whitney ranksum is shown  
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3.6.7.  Donor derived CD14+ cells can be kept in suspension and used in the as-
say, replacing uThp-1 cells: Proof of concept. 
CD14+ cells from a single Melbourne donor were isolated and used in a phagocytosis as-
say in replacement of uThp-1 cells. Cells were left to phagocytose for 40min and 90min, 
EtBr-stained CS2 pRBC either unopsonised or opsonised with PPS were used as targets 
for phagocytosis. The results obtained suggest that, as for uThp-1, 40min are enough for 
the measurement of phagocytosis and, at least for CS2 pRBC, there is no phagocytosis of 
unopsonised parasites (Figure 3-10) 
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Figure 3-10 – Phagocytosis assay performed by CD14+ cells: proof of concept. 
Donor derived CD14+ cells were isolated from a Melbourne donor and used in the new phagocytosis assay 
replacing uThp-1 cells. Cells were allowed to phagocytose for 40min or 90min EtBr-stained CS2 pRBC opson-
ised with positive serum (PPS) or unopsonised (Unop). Assay was conducted in triplicates. 
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3.7. Discussion 
3.7.1.  uThp-1 cells can perform phagocytosis and represent an alternative over 
the use of differentiated cells for the measurement of Fc-Receptor me-
diated phagocytosis 
Undifferentiated Thp-1 cells had previously been shown to be useful in measuring eryt-
hrophagocytosis [110], but no high-throughput assay concerning Fc-mediated phagocyto-
sis that could actually be used consistently on large sample sets existed.  
In this chapter a new, high-throughput method has been developed and tested in order to 
accurately and rapidly estimate Fc-receptor mediated phagocytosis induced by P. falcipa-
rum malaria-specific antibodies.  
This new method facilitates the measurement of functional antibodies to malaria VSA in 
large sample sets. Based on the use of undifferentiated Thp-1 cells that grow in suspen-
sion, this assay lends itself to various small modifications that might be used to study both 
the effector cell response to pRBC expressing specific ligands, and the antibody re-
sponses to these pRBC. Although this method and the bulk of the work presented in this 
chapter was not designed to directly compare the dThp-1 assay [6, 21, 111] with the new 
uThp-1 assay, I believe it is important to make comparisons, where comparisons can be 
made. There are several pertinent differences between the two assays, as can be seen in 
Table 3-1.  
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Table 3-1 – Main differences between the new uThp-1 assay and the commonly used dThp-1 assay 
 Comparison between phagocytosis assay done using undifferentiated Thp-1 cells (used in this study) and 
chemically- differentiated Thp-1 cells. * these parameters were not evaluated in these thesis, but can logically 
be derived from characteristics of both cell types/assays. 
  
New assay Commonly used assay 
Undifferentiated Thp-1 assay (uThp-1) Differentiated Thp-1 (dThp-1) 
Cells plated and used in the same day Cells plated, stimulated and used 3 days later 
Cells in suspension Cells are adherent 
56 Samples per 1 day/Assay (triplicate) 36 Samples per 3 day/Assay (triplicate) 
Fluorescence based Assay – FACS Colorimetric  based assay- Plate reader 
Read-out: Percentage of phagocytic cells that have 
ingested labelled pRBC  
Read-out: Amount of haemoglobin released by lysis 
of phagocytic cells 
Possibility of including other parameters in the study 
(e.g. cell surface markers)* 
Only one parameter measured 
Phagocytic cells readily accessible for further studies* Phagocytic cells destroyed 
Phagocytosis almost exclusively via Fc-receptors 
Phagocytosis through various recep-
tors/mechanisms* 
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The new uThp-1 assay is able to run 168 samples (in triplicates) over the time period that 
takes the dThp-1 assay to run 36 samples (in triplicates), thus providing a much more 
time-saving method not to mention a more suitable one to use with large sample sets. The 
high consistency of intra-assay results (Figure 3-5) permits us to run the assay in dupli-
cates instead of triplicates thus increasing even more the amount of samples that can be 
measured. The use of FACS allows us to have an immediate perception of the amount of 
cells present in the wells when acquiring the results (through the rate at which cells are 
acquired, which is relative to their concentration), something that cannot be done in the 
dThp-1 assay where each well has to be observed under a light microscope if we want to 
verify an even distribution of dThp-1 cells in the well (not to mention that no feasible cell 
count can be made).  
Using this assay on a large number of serum samples from pregnant women proved that 
this is a fast, reliable and sensitive method for the detection of phagocytic antibodies in 
human cohorts . Nevertheless, from the work presented in this thesis, it is difficult to com-
pare the efficacy of both the uThp-1 and the dThp-1 methods in the detection of clinically 
relevant information with regards to antibodies towards P. falciparum VSA since these as-
says were conducted by different people, using different controls and different methods of 
analysis of results [6].  
3.7.2.  Standard curves 
The use of standard curves in the new assay allows the immediate comparison of the be-
haviour of the uThp-1 cells across different experimental days and as such is an assur-
ance of inter-assay consistency of results. Standard curves, should ideally be made with 
the use of an antibody that will opsonise the surface of the pRBC, irrespective of the 
amount of parasite VSA present, or of the parasite line used. It was with this in mind that I 
started using the Rabbit polyclonal anti-human RBC antibody.  
3.7.3.  Fc-Receptor mediated phagocytosis 
Undifferentiated Thp-1 cells look to be of particular interest in the study of phagocytic anti-
bodies since it is clear that the IgG-mediated phagocytosis is performed through Fc re-
ceptors I and II, the only Fcγ receptors present in these cells [97]. Of note, uThp-1 cells do 
not express CD36 [29] a known cell-membrane receptor that can promote phagocytosis of 
unopsonised pRBC [30]. Undifferentiated Thp-1 cells were unable to phagocytose un-
opsonised pRBC of the CD36-binding parasite line 3D7, and also, although uThp-1 ex-
press ICAM-1, the ICAM-binding parasite line E8B-ICAM did not trigger a phagocytic re-
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sponse in the absence of immune serum, demonstrating that cytoadherence per se does 
not trigger uThp-1-mediated phagocytosis. 
Although exposed to CytoD concentrations shown to be able to inhibit the phagocytic ac-
tivity of macrophages [112], uThp-1 cells were still able to perform some phagocytosis of 
opsonised pRBC. This may represent a poor uptake of CytoD by the cells or a lack of ef-
fect of this compound on these particular cells. Since no studies of the effect of this drug 
on uThp-1 cells were done so far, it is difficult to dissect the reasons why phagocytosis 
was still performed. It was not the goal of this thesis, though, to dissect molecular mecha-
nisms behind the phagocytic process of Thp-1 cells. That the uptake of pRBC opsonised 
with IgG was mediated by Fc-Receptors, was clearly demonstrated by the use of Fc-
Block. This blocking agent is nothing more that the Fc‟ portion of human IgG and thus 
binds to Fcγ receptors preventing the binding of subsequent IgG (Figure 3-7).  
3.7.4.  Assay plasticity and future studies 
The assays reported here were performed using GFP expressing parasites and EtBr 
stained parasites thus allowing for the study of virtually every parasite line. Although not 
shown in this thesis, with the proper controls and parasite lines (for instance a parasite 
line that is transfected with GFP and one with Red fluorescent protein, RFP), it is even 
possible to conduct studies using 2 parasite lines at the same time. This could be used, 
for example, to verify how the presence of a specific parasite type may affect the phago-
cytic response to a second type.  
Positively selected donor monocytic cells can ultimately also be used (Figure 3-10), which 
will permit the large scale study of variations in host phagocytic cell responses. If, for in-
stance, other parameters like cell surface molecules (e.g. CD80, CD86, CCR5) are in-
cluded in the assay and together with this, analysis of Fc-receptor polymorphisms [37] is 
conducted, then it is possible to start getting an idea of the potential that this assay carries 
for characterising function and phenotype of donor monocytes on a large scale. 
The development of a fast, accurate and sensitive method for the measurement of anti-
body responses to VSACSA provided the perfect tool for the study of PG and SG women 
performed in the following chapter. 
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4.1. Summary 
As was reviewed in Chapter 3 of this thesis, in malaria endemic areas, pregnant women, 
that would otherwise be protected from clinical malaria after acquiring a degree of immu-
nity over the years, suddenly become susceptible to it and can suffer from severe clinical 
outcomes like maternal anaemia [1-3], infant low birth weight [2, 4] and miscarriages [1]. 
Primigravidae (PG) are widely recognised as the most susceptible group of pregnant 
women [1-3]. Malaria in pregnancy (MiP) has been linked to the appearance of Plasmo-
dium falciparum (P. falciparum) parasites with the capacity to bind to the placenta of these 
women [3] by expressing a Variant Surface Antigen (VSA) that is able to bind Chondroitin 
Sulphate A (CSA) (VARCSA) [5, 6]. Susceptibility to MiP tends to decrease over successive 
pregnancies [1-3] in part because the development of antibodies towards these VARCSA 
confers a certain immunity. However, development of immunity to MiP in PG and SG, 
specifically, is still poorly understood [7, 8]. In those areas where HIV and P. falciparum 
co-exist, higher rates of malaria infection, higher densities and prevalence of parasitaemia 
and lower levels of antibodies to pregnancy-specific VSA are associated with HIV infection 
making the combined presence of both HIV and malaria particularly deleterious for the 
health of both mothers and newborns [9-13]. Also, antibodies that specifically contribute to 
the phagocytosis of opsonised pRBC were shown to be decreased in the serum of HIV-
positive MG women but reported missing in PG [14]. 
Using the new phagocytosis assay I developed (see Chapter 3), I decided to look at PG 
and SG from the same cohort separately and to determine the presence of phagocytic an-
tibodies in these two groups of women and to evaluate the impact that a co-infection with 
HIV would have. The relationship between the presence and level of these antibodies with 
the occurrence or protection from adverse clinical outcomes was also assessed. I was 
able to show that PG are able to respond quickly to infection and to develop phagocytic 
antibodies and that the acquisition of these antibodies is severely impaired by HIV. In PG, 
phagocytic antibodies were not associated with protection from complications of MiP but I 
hypothesised that the presence of phagocytic antibodies would be more important during 
a second pregnancy. With that in mind I analysed the group of SG in the same cohort and 
was able to show that, indeed, phagocytic antibodies at delivery protect from infant birth 
weight, independently of age, maternal weight or HIV status. 
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4.2. Literature Review  
4.2.1. Primigravidae and Secundigravidae: humoral immunity to malaria in 
pregnancy 
4.2.1.1. The early years 
Until the second half of the last decade of the 20th century almost nothing more was 
known about how MiP affected PG and SG women than was already know for almost 40 
years before that [1-3]. This knowledge was based on observations that could not easily 
be explained. It had been observed that pregnant women were more susceptible to ma-
laria than their non-pregnant counterparts and that, among these pregnant women, PG 
were the most affected, suffering from severe anaemia and delivering low birth weight 
(LBW) babies [1-3]. Antibodies generated towards malaria during pregnancy had been the 
focus of some interest and since the late 1960s, early 1970s, were even known to be 
mainly of the IgG class [15, 16], but at this time the field of antibody-mediated immune re-
sponse during MiP was non-existent and would remain so for a few years more. During 
the 1980‟s, although the puzzle over what made PG so much more susceptible continued, 
few studies addressed this question. Investigations regarding the possibility that de-
creased antibody levels could explain susceptibility were hindered due to the lack of 
knowledge of the unique parasite phenotypes infecting these women against which anti-
bodies could be tested, (this would be available in subsequent years) The few studies that 
looked into antibodies towards MiP, and especially in PG, failed to detect any consistent 
associations between an antibody response, or even the lack of one, with MiP and its gra-
vidity-dependent severity [17-19].  
4.2.1.2. First measures of levels of antibody: before CSA. 
The observation by Adele et al [20] that IgG was present in the sera of Caucasian patients 
experimentally infected with Plasmodium vivax (P. vivax) prompted investigators to search 
for these anti-plasmodia antibodies in populations resident in malaria endemic countries. 
Pregnant women were the study population chosen by Williams et al [15] to show that in-
deed these IgG antibodies were present.  
Early studies that specifically addressed the antibody response of PG mainly used anti-
gens derived from peripheral-type parasites and/or ring-stage parasites, like the ring-
infected erythrocyte surface antigen (RESA). It is not clear why researchers at this point 
had not taken into account the earlier studies of Williams et al [21] showing how a malarial 
antigen derived from the placenta could be obtained, but one might speculate that re-
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searchers at that time did not consider placental parasites to be any different from the 
ones found in the periphery. It is also worthwhile mentioning that this search for anti-
malarial antibodies in pregnant women was not so much focused on the process of MiP 
but instead on understanding how maternal immunity resulted in conferred immunity for 
the newborn [22]. 
Deloron et al [18], interested in the high prevalence of MiP in PG compared to multigravi-
dae (women with 3 or more pregnancies, MG), compared the levels of anti-P. falciparum 
IgG antibodies in Nigerian nulligravidae (no pregnancies, NG), PG and MG and found 
fewer PG had anti-P. falciparum IgG compared to MG or NG, but these anti-P. falciparum 
IgG levels did not predict protection from infection, either individually or as a group. A lack 
of protection and a lack of association between antibodies towards whole pRBC or RESA 
peptides and gravidity was then shown in subsequent studies [19, 23-27]. At the time, as 
cortisol, a known immune-suppressor, was shown to be higher in PG it was proposed that 
cellular immune-suppression was responsible for the PG susceptibility. At this point SG 
were not the object of any particular study as an individual group, but were always in-
cluded in the MG group. The only relevant study that looked at SG was conducted by 
Fievet et al [28] in which they looked at cellular responses to several antigens (of malarial 
and non-malarial origins) during first pregnancy, after delivery and during a second preg-
nancy (always following the same women). They also looked at antibody levels but once 
again, and due to the use of RESA and a periphery-type parasite line, no major differ-
ences between groups were found as some antigens were higher in PG than SG, others 
were higher in SG, and others still outside of the context of pregnancy. 
4.2.1.3. Development of antibodies: the post CSA-adhesion era 
As was already mentioned, the discovery of CSA as an adhesion molecule for P. falcipa-
rum pRBC and its role in placental adhesion [5, 6] brought some light into an otherwise 
“shot in the dark” affair.  
Fried et al, in 1998, showed how antibodies towards CSA-binding parasite isolates from 
placentas could inhibit the CSA-binding phenotype and were more prevalent in MG and 
SG than in PG where, as it was reported in that paper, they were absent. They also found 
that serum from Asian women were able to inhibit the binding of African-derived parasite 
isolates to CSA and vice-versa, thus pointing to the existence of a geographically con-
served ligand in these parasites [29]. After this work, studies were able to find agglutinat-
ing [30, 31] and anti-adhesion antibodies [32] in PG , using both parasite isolates and a 
CSA-binding parasite line. Also, the gravidity-dependence demonstrated for susceptibility 
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to MiP could now be associated with the levels of these antibodies [31, 32] and thus bring 
an almost century year old question to rest.  
4.2.1.4. The kinetics of antibody production 
Now that the existence of antibodies towards CSA-binding P. falciparum isolates/lines 
seemed established, the question became: at what time during pregnancy did these anti-
bodies develop?  
O‟Neil-Dunne et al [33] published a study concerning the kinetics of production of antibod-
ies both in primigravidae and multigravidae from Yaounde in Cameroon, where the trans-
mission of malaria is perennial. They used a laboratory line, 3D7-CSA parasites, panned 
on placental CSPG (Chondroitin sulphate proteoglycan). Strangely, in this study, no anti-
bodies that inhibit adhesion of parasites to CSPG were found in multigravidae before 12-
16 weeks of gestation but high levels of antibodies ensued. Primigravidae only had anti-
bodies coming up at 20-24 weeks of gestation. After the 20-24 weeks of gestation period 
there were no differences between both groups of women in terms of the inhibitory anti-
body level. This seemed to be confirmed by other studies that also set the onset of anti-
body acquisition in PG at 20 weeks gestation [34]. Later studies have raised the possibility 
of these antibodies developing as early as the 10th week of gestation and a recent study 
by Aitken et al that made use of ultra-sound technology for the precise assessment of 
gestational age seems to point to 14 weeks of gestation, although this can actually be ear-
lier as 14 weeks was the minimal gestational age of enrolment for the study in question 
[35].  
4.2.1.5. Var2CSA and its domains: recognition by Primigravidae and Secundi-
gravidae 
The discovery of the var2csa parasite gene and its encoded VAR2CSA surface protein 
[36, 37], which seems to mediate the binding of placental-type parasites to CSA [36-39] 
led researchers to the identification of specific domains in this protein [40, 41] which not 
only mediate the binding to CSA but also towards which antibodies could be generated. 
The search for such antibodies and the specific domains to which they could bind showed 
that two domains in particular seem to be the targets of the immune response: DBL3X [42, 
43] and DBL5ε [43-45]. 
Primigravidae were shown to have antibodies that were able to bind to motifs in the 
DBL3X domain. The number of motifs recognised was inferior to the number of motifs 
recognised by MG [42]. This matched also the results obtained when looking at the rec-
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ognition of all the domains of VAR2CSA, where it was shown that PG had lower levels of 
antibodies to all of the domains when compared to MG [43]. It seems, though, that DBL5ε 
may constitute an important domain for PG. Guitard et al have shown that at delivery, un-
infected PG had higher levels of IgG3 towards DBL5ε than infected PG [44] while Brolin et 
al showed that DBL5ε is recognised in a parity-dependent pattern, contrary to DBL3X. 
Also, DBL5ε has been recently shown to possess epitopes that are recognised at different 
levels between PG and MG [46]. 
4.2.1.6. Antibodies and clinical outcomes: a protective role or a marker of in-
fection? 
There are a panoply of results obtained in the studies conducted so far regarding the pro-
tective role of antibodies during MiP and it seems that no particular pattern can be dis-
cerned for either PG or SG.  
Depending on the study, antibodies towards CSA-binding parasites were found to be as-
sociated with decreased placental parasitaemia or parasite density in SG [29, 31], in PG 
and SG [8], just in MG [34], in all gravid women [33], or even not associated at all [47]. 
Both maternal haemoglobin and infant birth weight can be negatively affected during MiP 
[1-4]. Antibodies directed at pRBC expressing VSACSA and that can protect pregnant 
women from these deleterious effects were first described in SG where they were associ-
ated with protection from low birth weight (LBW) babies [8], although this study was cross-
sectional and thus did not allow for a true protective verdict to be obtained. A relationshipp 
between antibody and protection was reported to be absent in both PG and MG, although 
the absence of an association in MG was suggested to be due to the presence of these 
antibodies in all MG women. Besides this study though, no other study was able to dem-
onstrate any protective effect of antibodies towards VSACSA in SG or PG as individual 
groups. 
What seems clear is that, at least for PG (for SG it is harder to conclude since not many 
studies consider this population independently), antibodies towards pRBC expressing 
VSACSA are a sound marker of placental Plasmodium infection. This has been observed in 
many studies [7, 31, 47, 48].  
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4.2.1.7. Determinants of humoral immunity 
4.2.1.7.1. Anti-malarial drugs and the use of Bed-Nets 
Early observations led researchers to conclude that the use of anti-malarial drugs had the 
capacity to decrease a pregnant woman‟s levels of anti-malarial antibodies, presumably 
due to a reduced amount of exposure to antigen [15, 18, 22, 49]. 
When antibodies towards VARCSA expressing parasites were investigated in PG receiving 
Intermittent Preventive Treatment (IPTp) with sulphadoxine pyrimethamine (SP) (refer to 
Chapter 3 for IPTp definition), it was shown that women receiving SP had lower levels of 
anti-VSACSA antibodies than women receiving placebo [50]. Interestingly, this study also 
showed that the antibody levels to non-CSA binding VSA were not affected by the receipt 
of IPTp-SP. A later study contradicted this result showing that no difference existed in the 
levels of antibodies to VSACSA in PG but this later study looked at a very small number of 
women [51]. Another recent study seems to point to PG having a low antibody response 
to VSACSA in the presence of IPTp, although this study also revealed low levels of P. falci-
parum infection [35]. 
No studies have, so far, looked specifically at the effect of insecticide-treated nets (ITNs) 
on the levels of antibodies towards VSACSA in PG or even in the general pregnant women 
population. One study, though, reports on the levels of antibodies to other antigens during 
pregnancy in a malaria-endemic area. This study, by Kariuki et al [52], analysed the anti-
body levels to merozoite and sporozoite antigens in pregnant women that reported using 
ITNs and found that some of these antibodies were decreased in women using ITNs while 
others were increased. The study failed to analyse the effect on PG and SG individually. 
4.2.1.7.2. HIV impact on levels of antibodies 
In areas where HIV and malaria co-exist, higher rates of malaria disease and higher den-
sities and prevalence of parasitaemia are seen among HIV-infected patients compared to 
those that are uninfected [9-11, 53].  
In pregnant women, the first study that looked at antibody levels in pregnant women in-
fected with HIV used several non-pregnancy-specific P. falciparum antigens and deter-
mined that for only one of those antigens (a peptide from the circumsporozoite protein) 
were antibody levels impaired in those women [54]. This led the authors to conclude that 
“increased susceptibility to malaria among HIV-infected pregnant women may not be ex-
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plained on the basis of their reduced antibody response to malaria antigens” [54]. Al-
though other studies seemed to point in this direction also, and reporting no association of 
HIV with a change in antibody levels even when looking at VSACSA antigens [7], it later 
became clear that HIV impair the antibody response of pregnant women. It was reported 
by Mount et al [55], using levels of agglutinating antibodies and total IgG to VSACSA, that 
pregnant women and particularly HIV-infected PG had lower levels of antibodies than HIV 
uninfected PG. In agreement with these results, Brolin et al [45] have shown that HIV-
positive PG seem not only to have less antibodies towards the VAR2CSA domain DBL5ε, 
but also that those antibodies have less affinity to their target. Nevertheless, others have 
reported that HIV-infected MG had a more pronounced humoral immune suppression than 
HIV-infected PG and SG [56] although it should be noticed that this study was done with 
very few samples (n=20) and using women that were all extremely immune-suppressed 
(only one woman out of 20 had a CD4 T cell count above 300x106 cells/L).  
4.2.2.  Aims of this Chapter 
In view of the known literature and of the limited knowledge that existed on the develop-
ment of phagocytic antibodies in PG and SG, the main aims of this part of the study were 
to: 
- Evaluate the presence of phagocytic antibodies in PG and SG; 
- Compare the sensitivity of the phagocytosis assay to measure antibodies when 
compared to total IgG to VSACSA; 
- Determine the relationship between an HIV co-infection and both the total IgG to 
VSACSA and phagocytic antibodies according to the different stages of placental in-
fection; 
- Determine the presence of associations between antibody levels and clinical out-
comes; 
4.3. Methods 
4.3.1.  Ethics statement  
The work presented in this chapter used samples from the MHP study cohort conducted in 
Blantyre, Malawi, which received ethical clearance from the College of Medical Research 
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and Ethics Committee, University of Malawi and the Melbourne Health Human Research 
Ethics Committee. 
1.1  Cell Cultures 
4.3.1.1. Plasmodium falciparum  
The parasite line CS2, which is an accepted model of MiP parasites [5, 47]), was used. 
This particular CS2 line was transfected with a plasmid containing a green fluorescent 
protein (GFP) expression cassette (kindly provided by Danny Wilson and James Beeson, 
WEHI) [57]. All parasite cultures were as described on Chapter 3, section 3.5.1.1. 
4.3.1.2. Culture of Thp-1 cells 
Culture of uThp-1 cells used in this part of the work was conducted exactly as described 
on Chapter 3, section 3.5.1.2. 
4.3.2.  The phagocytosis assay 
4.3.2.1. A standard phagocytosis assay using uThp-1 cells and CS2-GFP para-
sites 
Both the PG samples and the SG samples were studied using the exact same phagocyto-
sis method, with the exception that PG samples were run in triplicate and SG samples 
were run in duplicate. 
The phagocytosis assay and the analysis of the results obtained, as used in this part of 
the work was performed exactly as described on Chapter 3, section 3.5.2.1.  
4.3.3.  Total IgG to CS2VSA assay 
For PG samples this assay was performed by Wina Hasang.  
Flow cytometry was used to measure the total IgG levels to VSA expressed on CS2 pRBC 
(total IgG to CS2VSA) using a method described by Mount [55] with minor modifications. In 
summary, in a 96 well plate heat inactivated human sera (1:20 dilution) were co-incubated 
with 0.1% haematocrit of 3-8% parasitemia mid to late stage trophozoites PRBC in a total 
volume of 50μl PBS with 1% Foetal Bovine Serum (PBS/FBS) for 30 min (note parasites 
used in flow cytometry experiments were cultured and synchronized as described in 
(3.1.1.1). The PRBC were then washed thrice with PBS/FBS and co-incubated with 25 μl 
of polyclonal rabbit antihuman IgG antibody (DakoCytomation, Denmark) diluted 1:100 in 
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PBS/FBS for 30 min, washed again, and incubated with Alexafluor® 488 donkey anti-
rabbit IgG (Invitrogen, Eugene, Oregon USA), 1:500 in PBS/FBS with 10μg/ml ethidium 
bromide (EtBr) for 30 minutes. PRBC were then washed again and resuspended in PBS. 
Cells were gated based on forward and side scatter characteristics, and plotted by fluo-
rescence in channel 1 (Alexafluor® 488) and channel 2 (EtBr). The adjusted- geometric 
mean fluorescence intensity (MFI) for each sample was calculated by subtracting the MFI 
of non-infected RBC from that of gated EtBr-positive cells (ie PRBC): Adjusted MFI=MFI 
right quadrant – MFI left quadrant 
Sera from six individual malaria unexposed adults from Melbourne (Australian Red Cross 
Blood Service) were used as negative controls. The positive control was pooled serum 
from women with known high IgG levels to CS2VSA. The relative MFI (designated as the % 
of positive control) was then calculated using negative and positive controls. Disagreeing 
duplicates, defined as having an adjusted MFI variance greater than 20% from their mean 
and a relative MFI variance >10, were rerun (if possible) or excluded. Results were also 
discarded if flow cytometry plots did not show distinct cell populations. 
4.4. Results 
4.4.1.  Study samples and definitions used 
The serum samples used in this chapter came from a cohort which has previously been 
described [12, 55]. In brief, women in late third trimester of pregnancy gave written con-
sent to studies including HIV testing, and samples of peripheral blood were collected. Both 
PG and SG for whom results of placental histology sections had been obtained were in-
cluded in the present study, resulting in a total of 263 PG samples and 187 SG analysed.  
Placental tissue, collected at delivery, was fixed in formalin and Giemsa stained sections 
were examined histologically as previously described [65]. Placental malaria (PM) was 
considered to be present if there was evidence of parasites or pigmented monocytes or 
pigment in fibrin deposits in the placenta, irrespective of the presence of parasites in the 
peripheral blood (unless stated otherwise).  
For PG, and taking advantage of the numbers of samples obtained we were able to com-
bine histology findings with results of microscopy of Giemsa-stained placental and periph-
eral blood thick films to allocate women to one of four groups: No Malaria (no evidence of 
past or current malaria, either in blood films or placental histology), Acute Infection (pRBC 
on placental histology, without malaria pigment deposition), Chronic Infection (both pRBC 
and malaria pigment deposits on histology) and Past Infection (placental malaria pigment 
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deposits, without pRBC on histology or on blood films). We excluded from the grouping 
analysis women who presented only with peripheral parasitaemia. In all cases where 
parasites were present, all infections were with P. falciparum.  
Maternal anaemia (anaemia) was defined as a haemoglobin measurement of less than 
11.0 g/dL. Infant low birth weight (LBW) was considered to be a baby weight of less than 
2,500g 
4.4.2.  Primigravidae results 
4.4.2.1. HIV and Plasmodium infections: associations with maternal age, ma-
ternal haemoglobin and infant birth weight.  
Of the 263 women analysed in this study, 156 (60%) were negative for HIV, while 104 
(41%) revealed no evidence of a PM infection (Table 4-1).  
In a univariate analysis, using student‟s t-test (Table 4-1 – Characteristics of the PG study 
group and the associations of HIV and MiP with clinical outcome), both HIV and PM infec-
tion significantly decreased maternal haemoglobin levels and infant birth weight. The age 
of the women was significantly associated with both PM infection (being higher in unin-
fected women) and HIV (being higher in infected women). Women that were both infected 
with HIV and PM had lower birth weight babies and presented with lower levels of haemo-
globin than other groups (Table 4-1). 
When age, HIV status and PM status were included in a multivariate analysis using multi-
linear regression analysis, both haemoglobin levels (HIV: coef= -1.1, P=<0.0001; PM: 
coef= -0.8, P=0.002) and birth weight (HIV: coef= -238.7, P=<0.0001; PM: coef= -193.7, 
P=0.002) were associated with both infections, independently of maternal age. 
Since both maternal haemoglobin levels and infant birth weight can be expressed as the 
categorical clinical outcomes anaemia and LBW, respectively, the association of these 
with maternal age, HIV and PM infection was evaluated. Each of the infections, independ-
ently of maternal age, increased the prevalence of anaemia and LBW (Table 4-2). 
4.4.2.2.  Levels and spread of phagocytic antibodies and total IgG to CS2VSA 
As was discussed in Chapter 3 (see chapter 3) two parameters can be derived from the 
results obtained with the phagocytosis assay used in this study: the function and the titre 
of the antibodies. In this group of PG, both the titre and the function of phagocytic antibod-
ies correlated with the levels of IgG to CS2VSA (Spearman‟s rank correlation rho=0.48 and 
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0.50 respectively, p<0.0001) but, when a linear regression was performed, correlation be-
tween function of phagocytic antibodies and IgG to CS2VSA (r
2=0.56) was stronger than 
the one found between titres and IgG to CS2VSA (r
2=0.41) owing to their spread over a lar-
ger range of values (Figure 4-1). For further analysis, only the function of the phagocytic 
antibodies was used. I make use of the phagocytic antibodies‟ titre only where significant 
differences between the two parameters occurred.  
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Table 4-1 – Characteristics of the PG study group and the associations of HIV and MiP with clinical outcome 
    Age 
 
Maternal Hb level (g/dL)
1  
Infant Bw (g)
2 
  n [%] Mean (SD) p-value  n [%] Mean (SD) p-value  n [%] Mean (SD) p-value 
Entire Cohort  263 [100] 20.0 (3.3)    258 
[100] 
11.3 (1.98)    224 
[100] 
2904 (444)  
               
HIV negative 156 [60] 19.5 (2.7)   155 [60] 11.6 (1.96)   123 [55] 2982 (413)  
 positive 106 [40] 20.7 (3.9) 0.007   102[40] 10.8 (1.93) 0.002   100 [45] 2808 (466) 0.003 
               
Malaria infec-
tion 
negative 104 [41] 20.7 (3.6)   152 [60] 11.5 (1.91)   101 [45] 2978(416)  
 positive 151 [59] 19.6 (2.7) 0.0075   98 [40] 10.9 (2.00) 0.013   121[54] 2845(464) 0.016 
 Histology not present 8 [3]             
HIV and Mala-
ria: 
              
  DOUBLE NEGATIVES
3 
43 [16] 19.6 (2.8)   43 [16] 12.1 (1.66)   40 [18] 3158 (402)  
 
DOUBLE POSITIVES
4 
42 [16] 19.8 (3.0) 0.77   42 [16] 10.3(1.96) <0.0001
  
 41 [18] 2726 (559) 0.0001  
Data represents means (standard deviation from means), and numbers of subjects [percent of total for each parameter]. 
1
Maternal haemoglobin levels. 
2
Birth weight of ba-
bies at delivery. 
3
DOUBLE NEGATIVES are women with neither HIV nor malaria. 
4
DOUBLE POSITIVES are women with both HIV and malaria infection. Variables are nor-
mally distributed, so Student‟s t-tests were applied. Variables were analysed for all subjects for whom the relevant data were recorded. 
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Table 4-2 – Association of HIV and PM status with LBW and Anaemia 
  LBW
1 
[OR, (P-value), CI]
2 
Anaemia
1 
[OR, P-value, CI] 
HIV 2.24, (0.059), 0.97-5.18 2.35, (0.003), 1.32-4.16 
PM 2.69, (0.030), 1.10-6.59 2.60, (0.001), 1.45-4.66 
Maternal age 1.03, (0. 527), 0.93-1.16 1.02, (0.540), 0.95-1.11 
  
 
Logistic regression between HIV and PM status and the clinical outcomes LBW and Anaemia. 
1 
For low birth weight (LBW) and Anaemia definitions see section 4.4.1.  
2
 OR – Odds ratio, CI – 95% confidence interval 
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Figure 4-1 - Distribution of, and correlation between, the antibody parameters measured. 
A) Dot plot representation of the distribution of values obtained for total IgG to CS2VSA, and both phagocytic 
antibodies‟ parameters: function and titre. n= number of samples analysed in each group. B) linear regression 
analysis of IgG to CS2VSA and both function (open squares) and titre (full triangles)  of phagocytic antibodies. 
Analysis performed on GraphPad Prism v4.0 
4.4.2.3.  Phagocytic antibodies and Total IgG to CS2VSA are increased in P. fal-
ciparum infected women and decreased in HIV-infected women. 
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In a univariate analysis (Mann-Whitney ranksum), both phagocytic antibodies (Phago atb - 
Figure 4-2) and IgG to CS2VSA (Total IgG - Figure 4-3) were higher in women with evi-
dence of PM infection (Phago atb: z= 6.08, P < 0.0001; Total IgG: z= 4.83, P < 0.0001) 
and lower in HIV infected women (Phago atb: z= -3.75, P = 0.0002; Total IgG: z= -2.70, P 
= 0.007)  
4.4.2.4.  Phagocytic antibodies and total IgG to CS2VSA are not associated with 
changes in Infant birth weight, maternal haemoglobin or the clinical 
outcomes LBW and maternal anaemia.  
In a univariate analysis (Mann-Whitney ranksum), phagocytic antibodies were not associ-
ated with the presence of neither LBW infants (z= -0.692, P = 0.489) nor with the occur-
rence of maternal anaemia (z= -0.769, P = 0.442) (Figure 4-4 A and B). Phagocytic anti-
bodies also showed no associations, with infant birth weight (Spearman‟s correlation tests 
(rho) = -0.102, P= 0.121) nor with maternal haemoglobin levels (rho= 0.097, P= 0.117). 
Linear regression methods (Figure 4-4, C and D) were used to investigate causality be-
tween these parameters and also failed to detected any associations (infant birth weight: 
r2= 0.0065, P= 0.227; maternal anaemia: r2= 0.035, P= 0.342). 
Similarly, the levels of total IgG against CS2VSA were not associated with the presence of 
LBW infants (z= -0.149, 0.881) or maternal anaemia (z= -0.538, P= 0.591) (Figure 4-5, A 
and B), nor were they associated with infant birth weight (rho = -0.054, P=0.440) or ma-
ternal haemoglobin levels (rho = 0.035, P= 0.592). 
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Figure 4-2 – Effect of infections on phagocytic antibodies function 
Both the placental malaria status (upper graph) and the HIV status (lower graph) of the women affected the 
function of phagocytic antibodies towards the P. falciparum parasite line CS2-GFP. Mann-Whitney rank sum 
tests were applied to quantify the differences observed. 
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Figure 4-3 – Effect of infections on Total IgG to CS2VSA 
Both the placental malaria status (upper graph) and the HIV status (lower graph) of the women affected the 
total IgG to CS2VSA. Mann-Whitney rank sum tests were applied to quantify the differences observed. 
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Once more, linear regression analysis did not detect any correlation between phagocytic 
antibodies (infant birth weight: r2= 0.0035, P= 0.400; maternal anaemia: r2= 0.0026, P= 
0.437) nor total IgG to CS2VSA (infant birth weight: r
2= 0.0036, P= 0.406; maternal anae-
mia: r2= 0.0022, P= 0.508) (Figure 4-5, C and D). 
4.4.2.5.  Multivariate analysis highlights the impact of HIV on phagocytic anti-
bodies. 
In a multivariate analysis, using multiple linear regression methods, on P. falciparum posi-
tive women alone, HIV infection was associated with decreased levels of phagocytic anti-
bodies. Neither maternal haemoglobin levels, infant birth weight nor HIV were associated 
with the levels of total IgG to CS2VSA (Table 4-3). 
4.4.2.6.  The levels phagocytic antibodies and total IgG to CS2VSA are corre-
lated with the MiP histopathology groupings identified and are differ-
ently modulated by HIV infection 
When analysis of antibody measurements was made according to the PM status of the 
women, similar levels of both total IgG to CS2VSA and phagocytic antibodies were ob-
served in the groups with current or previous P. falciparum infection and no HIV (Figure 
4-6, light grey bars).  
When the relationship between placental malaria status and antibody measurements was 
analysed within the group of HIV positive women (Figure 4-6, dark grey bars), women in 
the acute infection group had significantly lower levels of total IgG to CS2VSA than women 
in the combined chronic and past groups (Mann-Whitney ranksum: p=0.018 and p=0.038, 
respectively, Figure 4-6A) and significantly lower phagocytic antibodies function than 
women in the chronic group (Mann-Whitney ranksum: p=0.034, Figure 4-6B).  
The comparison between antibody measurements in HIV positive and HIV negative 
women in the different histopathology groups revealed that HIV positive women in the 
acute group failed to generate antibodies to pRBC, having low levels of total IgG to CS2 
VSA (Mann-Whitney ranksum: p=0.028, Figure 4-6A) and low levels of phagocytic anti-
bodies (Mann-Whitney ranksum: p=0.013, Figure 4-6B), when compared to the HIV nega-
tive women. HIV positive and negative women in the chronic infection group had similar 
levels of antibodies. HIV infected women in the past infection group had lower levels of 
phagocytic antibodies than did HIV negative women in this group (Mann-Whitney rank-
sum: p=0.07).  
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Among HIV infected women, peripheral blood CD4 T-cell counts were found to be associ-
ated with levels of antibody to pRBC. HIV positive women who presented with a CD4-T 
cell count less than 350 x 106 cells/L had lower levels of IgG to CS2 VSA (coef: -6.15, 
P=0.007) and less phagocytic antibodies (coef: -11.95,P=0.002) than did HIV infected 
women with CD4 T-cell counts above 350 x106 cells/L 
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Figure 4-4 – Univariate analysis of phagocytic antibodies to CS2VSA and clinical outcomes in PG 
Box plots of phagocytic antibodies‟ function against the occurrence of infant low birth weight (A) and maternal 
anaemia (B). Mann-Whitney Ranksum tests were performed and no statistical significance was detected (see 
values in text). Scatter plots of phagocytic antibodies against infant birthweight (C) and maternal haemoglobin 
levels (D) showed no correlation between the parameters analysed after spearman‟s correlation tests and 
linear regression analysis (see values in text). 
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Figure 4-5 - Univariate analysis of total IgG to CS2VSA and clinical outcomes in PG 
Box plots of phagocytic antibodies‟ function against the occurrence of infant low birth weight (A) and maternal 
anaemia (B). Mann-Whitney Ranksum tests were performed and no statistical significance was detected (see 
values in text). Scatter plots of phagocytic antibodies against infant birthweight (C) and maternal haemoglobin 
levels (D) showed no correlation between the parameters analysed after spearman‟s correlation tests and 
linear regression analysis (see values in text). 
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Table 4-3 – Multivariate analysis of antibodies measured and clinical parameters analysed in PG 
Variables Phagocytic function   Total IgG to CS2  
 Multivariate analysis
1
   Multivariate analysis
1
  
 Coeff (95% CI) P   Coeff (95% CI) P  
      
Plac malaria  NA   NA 
      
HIV -10.97 (-21.33, -0.61)  0.038  -7.60 (-16.9, 1.68) 0.107 
      
Hemoglobin levels
2
 -0.99 (-3.36, 1.39) 0.412  -0.56 (-2.90, 1.78) 0.637 
      
      
Infant Birthweight
2
 0.001 (-0.009, 0.012) 0.834  0.002 (-0.008, 0.012) 0.708 
 
1
 Adjusted estimate for malaria positive women only (Multi linear model correlation coefficients and respective 
95% confidence intervals and P-values are shown). (NA) non-applicable, (Coeff) regression coefficient (95% 
CI) 95% confidence intervals. A negative coefficient implies a decrease of antibody levels. A positive coeffi-
cient implies an increase in antibody levels. 
Ricardo Ataíde 2011 
 
109 
 
 
Figure 4-6 – Antibody measurements across MiP histopathology groups in PG 
 Light grey bars – HIV negative (HIV-), dark grey bars – HIV positive (HIV+). A) Total IgG to CS2VSA. Mann-
Whitney ranksum tests performed on HIV- women: §acute vs chronic p=0.018, ‡ acute vs past: p= 0.038. 
Mann-Whitney ranksum tests performed between HIV- and HIV+ women: * acute group: p= 0.028. B) phago-
cytic antibodies‟ function. Mann-Whitney ranksum tests performed on HIV- women: § acute vs chronic 
p=0.034. Mann-Whitney ranksum tests performed between HIV- and HIV+ women: * acute group: p= 0.013, † 
past group: p= 0.07. Bars: median and interquartile ranges. Dots: outliers. 
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4.4.3.  Secundigravidae results 
4.4.3.1.  HIV and PM: associations with maternal age, maternal haemoglobin 
and infant birth weight in SG 
One hundred and eighty seven samples were available for this study to be conducted. 
Forty two percent of the SG had placental malaria and 65% were HIV infected (Table 4-4). 
Most women (62%) were anaemic, and the mean haemoglobin concentration ± standard 
deviation (SD) was 10.6±2.1 g/dL. Haemoglobin levels were not associated, in a univari-
ate analysis using Student‟s T-tests, with placental malaria infection or with HIV status in 
this study group (Table 4-4). Infant birth weight did not vary with PM infection, but was 
significantly lower among HIV-positive women (P < 0.001, Table 4-4). Women with evi-
dence of PM infection were significantly younger than uninfected women (P =0.002; Table 
4-4) 
When age, HIV status and PM status were included in a multivariate analysis using multi-
linear regression, infant birth weight was still associated with HIV infection and not PM in-
fection (HIV: coef= -369, P=<0.001; PM: coef= -27.5, P=0.721) while maternal haemoglo-
bin levels remained not associated with either infection (HIV: coef= -0.11, P=0.815; PM: 
coef= -0.52, P=0.205) independently of maternal age. 
Analysis of the relationship between HIV infection and PM infection and the outcomes 
LBW and maternal anaemia, using logistic regression methods, did not reveal any asso-
ciations that differed from the ones obtained with the continuous parameters (all P values 
>0.05). 
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Table 4-4 - Characteristics of the secundigravidae study group and the associations of HIV and MiP with clinical outcome 
     Age  
  
Maternal Hb 
level (g/dL)
1 
   
Infant Bw (g)
2  
  n [%] Mean (SD) p-value  n [%] Mean (SD) p-value  n [%] Mean (SD) p-value 
Entire Co-
hort 
 187 [100] 22.5 (3.1)    129 [100] 10.6 (2.14)    181 [100] 2852 (518)  
               
HIV negative 65 [35] 22.1(2.3)   30 [23] 10.7 (2.1)   61 [34] 3091 (452)  
 positive 122 [65] 22.7 (3.4) 0.197  99 [77] 10.6 (2.2) 0.934  120 [66] 2731 (510) <0.001 
               
Malaria in-
fection 
negative 89 [48] 23.1 (3.5)   58 [45] 10.9 (2.2)   87 [44] 2852 (561)  
 positive 79 [42] 21.6 (2.3) 0.002  61 [47] 10.5 (2.0) 0.252  78 [43] 2865 (438) 0.875 
 Not avail-
able 
19 [22]     10 [8]     16 [9]   
HIV and Ma-
laria: 
              
DOUBLE NEGATIVES
3 
27 [14] 22.3 (2.0)   9 [7] 11.1 (2.4)   26 [14] 3112 (501)  
DOUBLE POSITIVES
4 
47 [25] 21.5 (2.1) 0.119  42 [33] 10.5 (2.0) 0.404  46 [25] 2714 (390) <0.001 
            
 
The data represents numbers of patients (percentages of total for each parameter) and means [standard deviations]. 
1
Maternal haemoglobin levels. 
2
Birth weight of babies 
at delivery. 
3
DOUBLE NEGATIVES are women with neither HIV nor malaria. 
4
DOUBLE POSITIVES are women with both HIV and malaria infection. Variables are normally 
distributed, so Student‟s t-tests were applied 
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4.4.3.2.  Levels and spread of phagocytic antibodies and total IgG to CS2VSA in 
secundigravidae 
The correlation between the levels of total IgG to CS2VSA and the phagocytic function in 
this cohort of SG women was similar, although slightly higher, to the one found in the PG 
group (r2=0.67, Figure 4-7A). The value for Spearman‟s rank correlation was also slightly 
higher (rho= 0.61, P<0.001). The spread of values for total IgG to CS2VSA was larger than 
that for phagocytic antibodies (Figure 4-7B). 
4.4.3.3.  Associations between antibody levels and HIV, Placental malaria 
status, maternal haemoglobin and infants’ birth weight in Secundigra-
vidae 
We compared antibody levels in women with current placental malaria infection (PM+) and 
without infection (PM-) using Mann-Whitney ranksum tests. For phagocytic antibodies, 
levels were higher in PM+ women than in PM- women (z = 4.54, P<0.001, Figure 4-8B). 
Similarly, total IgG to CS2VSA was higher in PM+ women than PM- women (z = 4.03; 
p<0.001, Figure 4-8D). Phagocytic antibodies were significantly decreased in HIV infected 
women compared to HIV uninfected women (z = -2.55, P=0.011, Figure 4-8A), whereas 
total IgG to CS2VSA showed a non-significant difference between HIV-infected women and 
women who were HIV-negative (z= -1.76, P=0.079; Figure 4-8C).  
Using linear regression methods, neither phagocytic antibodies nor total IgG to CS2VSA 
were correlated with maternal haemoglobin levels. Infant birth weight was correlated with 
phagocytic antibodies (coef=3.34, p= 0.034) (Figure 4-9A) but not associated with total 
IgG to CS2VSA (coef= 0.007, p=0.223) (Figure 4-9B).  
A multivariate analysis was performed using HIV status, antibodies and maternal age and 
weight against infant birth weight and maternal haemoglobin concentration. Women were 
divided into PM+ and PM-. Total IgG to CS2VSA was not associated with significant 
changes in infant birth weight in either group (data not shown). Phagocytic antibodies 
were not associated with infant birth weight in PM- women (LR: coef= 0.42, p=0.902). In 
contrast, in PM+ women, the function of phagocytic antibodies was found to be signifi-
cantly associated with birth weight (LR: coef= 3.57, p=0.025), independently of HIV status, 
maternal age and weight. It is important to point out that both HIV status and maternal 
weight were independently associated with infant birthweight in PM- and PM+ women. 
Neither antibody measurement was associated with maternal haemoglobin levels in multi-
variate analyses (Table 4-5).  
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Figure 4-7 – Correlation and spread of antibodies parameters measured in SG 
The correlation (top graph) between phagocytic antibodies and total IgG to CS2VSA was evaluated by linear 
regression and Spearman‟s rank correlation (values in text). Both the linear regression and the 95% confi-
dence interval are plotted. The dotplot spreads of the two parameters measured (lower graph), phagocytic 
antibodies (phago) and total IgG to CS2VSA (total IgG), are plotted alongside the medians.  
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Figure 4-8 – Univariate analysis of antibodies measured versus HIV and placental malaria in Secundi-
gravidae 
Both phagocytic antibodies (A and B) and total IgG to CS2VSA (C and D) were significantly modulated by HIV 
(left panels) and PM (right panels). A univariate analysis was performed using Mann-Whitney rank sum tests. 
Box, median and interquartile range; whiskers, lowest and highest values. P values are shown.  
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Figure 4-9 – Univariate association between infant birth weight and the anti- CS2VSA antibodies meas-
ured in Secundigravidae 
Univariate linear regression of phagocytic antibodies (A) and total IgG to CS2VSA (B) with infant birth weight. 
Both P-values are plotted. Only phagocytic antibodies correlated with infant birth weight (r
2
=0.025, p=0.034). 
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HIV modulates phagocytic antibodies in the ‘No Malaria’ histopathology group 
in Secundigravidae 
Although the numbers of SG samples available to perform this study (n=187) did not allow 
for a conclusive analysis of HIV effect according to PM histopathology groups it was pos-
sible to verify that the levels of total IgG to CS2VSA and of phagocytic antibodies did not 
vary according to findings on placental histology, (data not shown), being similar in 
women with acute, chronic and past infection (Anova across groups, Total IgG to CS2VSA: 
p=0.266; phago: p=0.429).  
Of notice, in the histopathology group „No Malaria‟, in which there was sufficient numbers 
available for analysis (n=109), HIV significantly affected the function of phagocytic anti-
bodies (z =-2.17, P= 0.03, Figure 4-10A) but not the total IgG to CS2VSA (Z= -1.35, P= 
0.179, Figure 4-10B). 
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Table 4-5 – Multivariate analysis of infant birth weight in Secundigravidae according to Placental ma-
laria status 
Variables PM negative   PM positive  
 Multivariate analysis
1
   Multivariate analysis
1
  
 Coeff (95% CI) P   Coeff (95% CI) P  
      
Infant birth weight (g) NA   NA  
      
Phagocytic function 0.42 (-6.28, 7.11) 0.902  3.57 (0.461, 6.68) 0.025 
    -  
HIV -257.46 (-21.33, -0.61)  0.043  -272.46 (-462.57, -82.35) 0.006 
      
Maternal weight (Kg) 31.42 (17.83, 45.01) <0.001  13.37 (1.23, 25.51) 0.031 
      
Maternal age (years) -2.38 (-33.07, 28.30) 0.878  -1.28 (-39.69, 37.13) 0.947 
 
1
 Multilinear regression analysis of infant birth weight (in grams) against phagocytic antibodies function, HIV 
status, maternal weight (in kilograms) and maternal age in Placental malaria (PM) positive and negative 
women. Multi linear model correlation coefficients and respective 95% confidence intervals and P-values are 
shown. (NA) non-applicable, (Coeff) regression coefficient (95% CI) 95% confidence intervals. A negative co-
efficient implies a decrease of infant birth weight. A positive coefficient implies an increase in antibody levels. 
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Figure 4-10 – Effect of HIV on the anti-CS2VSA antibody levels in the SG ‘No Malaria’ histopathology 
group. 
In a univariate analysis of women that showed no evidence of placental malaria infection, using Mann-Whitney 
ranksum tests, phagocytic antibodies (A) are shown to be significantly modulated by HIV infection, contrary to 
total IgG to CS2VSA (B). Box, median and interquartile range; whiskers, lowest and highest values. P values 
are shown. 
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4.5.  Discussion 
It is important to start this discussion by pointing out that due to technical constraints (es-
sentially the use of different positive controls for both PG and SG) it was not possible to 
directly compare the results of the two groups of women, which would have been ideal. 
Nevertheless, we can compare the results that were obtained within the individual groups 
and although a quantitative approach cannot be obtained, it is possible to make a qualita-
tive comparison of the results of both groups. 
4.5.1.  Primigravidae 
4.5.1.1.  Both HIV and Placental malaria have a negative impact on the clinical 
outcomes of pregnancy 
Both HIV and malaria were strongly and independently associated with the occurrence of 
low maternal haemoglobin and lower birth weight babies, and as was expected, co-
infected women and their babies had the worst outcomes (Table 4-1) [10, 66]. This occurs 
independently of maternal age as revealed by using multilinear regression analysis. It is 
interesting to point out that HIV seemed to have a bigger impact on the birth weight of the 
infants than did PM: HIV associated with a loss of 238.7g when compared to the mean 
birth weight while PM represented a loss of 193.7g. This revealed to be independent of 
maternal age and maternal weight by multilinear regression analysis (data not shown). 
This is revealing of the possible impact on the maternal and infant health that interven-
tions that target either HIV or malaria infections in this particular group of women might 
have. The clinical outcomes maternal anaemia and LBW were also more prevalent in 
women that presented with these infections (Table 4-2). 
4.5.1.2. Antibodies to CS2VSA: Function, Titre and Total IgG 
Levels of total IgG to CS2 VSA as well as function elicited by phagocytic antibodies had a 
larger spread than the actual titre of the phagocytic antibodies observed (Figure 4-1A), 
and we postulate that this is due to the limited exposure of PG in this study to pregnancy-
specific parasites. In cohorts of MG, with longer histories of exposure and a more devel-
oped pregnancy-specific immunity, titres of phagocytic antibodies may have a larger 
spread, and may thus be more informative. The choice of function or titre for analysis is 
dependent on the research question, on the characteristics of the study population, etc., 
but both parameters (function and titre) can provide valuable information. 
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Not all antibodies that are able to target the surface of the pRBC are immediately associ-
ated with a specific function. According to the IgG sub-class to which the antibodies be-
long there are a number of functions that can be attributed to them, as was reviewed in 
Chapter 3 [14, 67-71]. Although in this study there was no attempt at associating the sub-
class of IgG present in the serum samples with the amount of phagocytosis obtained 
(which has already been the focus of different studies [68, 72]), I was nonetheless inter-
ested in the correlation between the total IgG to CS2VSA and the phagocytosis levels ob-
tained. In this study group of PG the correlation between those two antibody measure-
ments was about 48% by Spearman‟s rank and about 56% by linear regression (see sec-
tion 4.4.2.2 and Figure 4-1B). These values give us an idea of how the values of one 
measurement co-vary (Spearman‟s rank) and how strong is one of the measurements in 
predicting the other (linear regression). 
4.5.1.3. Phagocytic antibodies to CS2VSA are decreased in HIV-infected women 
and are not associated with protection 
Antibodies towards CS2VSA (in this case measured by phagocytosis assays or total IgG 
assays) were found to be elevated in women who presented with evidence of current or 
past Plasmodium falciparum infection in their placentas. It seems well established that 
these anti-VSACSA antibodies represent a good marker of infection in PG [7, 31, 47, 48] 
(Figure 4-2A, Figure 4-3A) at delivery.  
Levels of IgG to CS2VSA and phagocytic antibodies were lower in HIV positive women 
when compared to HIV negative women (Figure 4-2B, Figure 4-3B), as had been sug-
gested by other studies [55]. 
In our cohort of PG, antibodies to CS2VSA were not found to be associated with protection 
from LBW or low maternal haemoglobin levels (known to be important outcomes associ-
ated with placental malaria (reviewed in [73, 74]) (Figure 4-4 and Figure 4-5), instead an-
tibodies reflect mainly exposure to antigen. Similar results, with a lack of association be-
tween adverse outcomes and presence of antibodies to MiP related antigens, have re-
cently been published [51]. It may be possible that a certain titre and “quality” of such an-
tibodies has to be present in circulation at very early stages during the pregnancy for a 
protective effect (or an association with one) to be observed, something already sug-
gested by other studies [8, 51, 75]. Only studies spanning from pre-pregnancy until deliv-
ery looking at these antibodies would be able to answer this question convincingly. 
In a multivariate analysis including HIV, maternal haemoglobin level and infant birth 
weight, using the malaria infected women, HIV was found to be associated with a de-
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crease of phagocytic antibodies function but not of levels of IgG to CS2VSA( Table 4-3). A 
similar result with HIV affecting phagocytic antibodies function (opsonic-activity) but not 
other types of antibody was obtained by Jaworowski et al, using MG women from this 
same study cohort [12]. This raises two distinct possibilities: either HIV impacts differently 
on the production of functionally distinct antibodies (as suggested also by [14]) and/or the 
new phagocytosis assay is more sensitive for the detection of small differences between 
groups. 
4.5.1.4. HIV impacts greatly on the acquisition of antibodies to VSACSA 
When the women were grouped according to their PM status, measures of the function of 
phagocytic antibodies and the total IgG to CS2VSA tended to vary between current, chronic 
and past placental infection. Antibody levels were highest in the women with chronic infec-
tion (as observed by others [7]), supporting the view that constant exposure to MiP-type 
parasites increases production of anti-VSACSA antibodies. Unlike the previously mentioned 
study, which included women of all gravidities, this study focussed solely on PG, indicat-
ing that a single pregnancy where chronic infection is present is sufficient to generate 
strong anti-VSA antibody responses. In the absence of HIV infection, the levels of anti-
body in acute infection were very similar to those in chronic infection, suggesting that ro-
bust antibody responses to these antigens can develop rapidly, as observed also in other 
studies [75] (Figure 4-6). Further investigation of the relationship between placental histo-
pathology, duration of infection and levels of antibodies in HIV positive versus HIV nega-
tive women would be of significant interest in confirming the differences observed.  
Grouping according to PM status provides also a putative timeline of exposure to preg-
nancy specific antigens and of antibody acquisition: Women with „No Malaria‟ may have 
had little or no exposure to antigen. In „Acute Infection‟, antibody responses are develop-
ing, following recent exposure to antigen. „Chronic Infection‟ represents repeated expo-
sure to antigen, and antibody maturation and/or recall, and „Past Infection‟ is associated 
with antibody maintenance, following past exposure to antigen. This is in keeping with es-
tablished paradigms of the time course of placental infection [76]. 
When analysed under this classification it seems that HIV infection reduced the genera-
tion of antibodies and possibly affected the maintenance of antibodies after clearance of 
malaria infection, when comparing HIV-positive with HIV-negative women. Although the 
time-frame of one pregnancy is probably not ample enough to fully assess the impact that 
HIV can have on the maintenance of antibody repertoires, it is well established that HIV 
negatively influences memory B cells, impairing the long-term serological memory of the 
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infected individuals [77, 78]. Future studies looking at the levels of these same antibodies 
six months after delivery or in subsequent pregnancies in HIV negative and HIV positive 
women and comparing numbers and activity of memory B-cells may prove to be more in-
formative. Even, so, and since phagocytic antibodies seem to be more affected by HIV 
than total IgG to CS2VSA I hypothesised that this difference would be of seminal impor-
tance when a second pregnancy starts since HIV positive women would have, theoreti-
cally, less phagocytic antibodies than HIV negative women. 
In the chronic infection group, HIV did not seem to impact on the level of IgG to CS2 VSA 
or function of these antibodies, suggesting that a longer exposure period may overcome 
the impairment in antibody production elicited by HIV infection. 
4.5.2.  Secundigravidae 
4.5.2.1. PM does not associate with clinical outcomes. HIV associates with 
lower infant birth weight. 
The mean haemoglobin level of the women participating in this study was low (mean= 
10.6 g/dL), but the exact cause of this high prevalence of anaemia is unknown, and likely 
to be multifactorial in this population [79]. Probably as a consequence of those low levels, 
haemoglobin levels did not differ between HIV negative and HIV positive women, nor be-
tween women with and without PM. HIV infection, but not PM, significantly influenced in-
fant birth weight (Table 4-4). 
4.5.2.2.  Antibody levels: spread and correlations between antibodies meas-
ured 
The correlation between total IgG to CS2VSA and phagocytic antibodies observed was 
similar in strength in both the SG and PG from the same cohort (Figure 4-7A). It is inter-
esting to note, though, that the values for both the Spearman‟s rank correlation and the 
linear regression are slightly higher in the SG group than in the PG group (see sections 
4.4.2.2 and 4.4.3.2), something that I will discuss below. The spread of the antibodies 
measured revealed a higher spread for total IgG to CS2VSA in this SG group (Figure 4-7B), 
reflecting, I hypothesise, the recall of immunity from previous exposures. 
4.5.2.3. Associations of antibodies measured with HIV and PM 
Both phagocytic antibodies and total IgG to CS2VSA were higher in PM+ women than in 
PM- women. HIV appeared to have significantly greater impact on phagocytic antibodies 
than on total IgG to CS2VSA (Figure 4-8). This impact of HIV supports the view that either, 
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in cohorts of women infected with HIV, IgG sub-classes that contribute to phagocytosis 
are more impaired than those that do not or that the phagocytosis assay developed is a 
more sensitive way of detecting these differences. Several studies have shown that differ-
ent functional antibodies and even levels of total antibodies do not always correlate well 
with each other when controlling for gravidity or HIV [12, 14, 80]. 
4.5.2.4. Association of infant birth weight with phagocytic antibodies 
When a univariate analysis of infant birth weight and maternal haemoglobin levels was 
performed against the antibodies measured, infant birth weight revealed a significant as-
sociation with phagocytic antibodies but not total IgG to CS2VSA (Figure 4-9). I tried to dis-
sect this association by including in the analysis parameters that are associated with 
changes in low birth weight. When the women were divided according to presence or ab-
sence of PM, levels of total IgG to CS2VSA were still not associated with birth weight or 
haemoglobin levels in either group. On the other hand, phagocytic antibodies to CS2VSA 
within PM+ women remained associated with infant birth weight even after controlling for 
HIV, maternal age and maternal weight. Infant birth weight increased 3.57g per unit of an-
tibody measured (coef= 3.57, p=0.025) (Table 4-5). These observations have similarities 
to those of Duffy et al, who measured anti-adhesion antibodies and identified SG as a par-
ticular important group in the search for associations between antibodies and outcomes 
[8]. 
4.5.3.  Antibodies towards VSACSA in Primigravidae and Secundigravidae: an at-
tempt at a final discussion 
As I specified earlier, it is not possible to directly compare the results of the two groups of 
women. Nevertheless, I believe that by comparing some of the results obtained with one 
and the other it is possible to begin to paint the picture of how in the context of HIV infec-
tion, immunity against MiP is being developed. Although an attempt for a rational and fac-
tual discussion is going to be made, it is unavoidable to enter the realm of speculation at 
times, and I hope that this discussion can foster the development of new ideas. 
I would like to start by stating that I believe that in cases when longitudinal studies are not 
able to be performed, cross-sectional studies of antibody levels against MiP-type antigens 
should take placental histopathology results in consideration and not depend on the pres-
ence or absence of parasites in the peripheral circulation, or the placental circulation only. 
Taking placental histopathology results in consideration allows us not to (or at least to 
minimise it considerably) overlook cases of past infections that were resolved, and that 
Ricardo Ataíde 2011 
 
124 
 
might have significantly contributed for the levels of antibodies that are being detected at 
the time of collection of samples.  
In this study, the effect that HIV had on the levels of antibodies measured in PG was quite 
dramatic and we were able to give a tentative explanation of how this occurred by making 
use of the histopathology grading of the placentas of the women involved. This revealed 
that it is during the acquisition of immunity that HIV seems to impact on the immunity to 
new antigens, which in this case were MiP-type parasites. Besides this, phagocytic anti-
bodies in HIV positive women that had evidence of past infections also seemed to have 
lower levels than in women that were HIV negative. This led me to hypothesise that, if 
these women were to have a second pregnancy, those that had higher levels of antibod-
ies, from their first pregnancy, would be able to fight a second PM infection better. So, and 
despite revealing to be only a marker of infection in the PG group, these phagocytic anti-
bodies could actually be protective in SG. It was with this in mind that I decided to investi-
gate a group of SG for which the placental histopathology results were also available.  
Although the numbers of women were not enough to completely dissect the role of these 
antibodies according to the different PM groups, the fact that in the „No malaria‟ group HIV 
positive women had lower levels of phagocytic antibodies than did HIV negative women 
(with no significant differences for total IgG to CS2VSA) seems to confirm the results ob-
tained in the PG group for women with past infection. The significant effect that having 
phagocytic antibodies had on the infant birth weight in the SG women, may reflect a very 
important parameter that I was not able to assess during this study but which I (together 
with others) believe to be important to determine and to which I alluded before: probably a 
certain titre and “quality” of antibodies has to be present in circulation at very early stages 
during the pregnancy for a protective effect (or an association with one) to be observed [8, 
51, 75]. As such, being in a position of transition between susceptible PG and immune 
MG, SG can be an important group for the detection of associations between antibodies 
and clinical outcomes and thus present a very interesting focus of research. 
4.5.4.  Final remarks and future directions 
This study was primarily directed at looking at the effects of HIV on a PG group of women 
who are the group more likely to suffer from MiP. The study on SG women that followed, 
was the result of observations made in the first study and revealed and consolidated the 
idea that these two groups of pregnant women sufficiently different from each other (and 
probably from MG, though I did not analyse MG in this study), to be analysed separately 
and even be the subject of independently designed studies. 
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It is not possible to conclude with absolute certainty that the results obtained in this study 
will be applicable to all populations of African pregnant women since it is well established 
that the dynamics of infection (both HIV and malaria) highly influence the way in which 
these two interact [11, 53]. Nevertheless, there are several points that can be taken and 
tested in different settings. Although the effects of anti-malarial treatment were not evalu-
ated, it is clear that HIV should be fought from the onset of pregnancy in PG so as to allow 
for the generation of immunity against MiP. This immunity is likely to be of importance for 
the outcomes of subsequent pregnancies. Together with this, interventions that target ma-
ternal mal-nutrition should be used in order to increase maternal well-being and as re-
vealed in the SG study, minimise the adverse outcomes of maternal HIV infection on the 
infants. 
Longitudinal studies that are conducted specifically to look at the development of immunity 
during pregnancy in HIV positive versus HIV negative women from PG to SG would, no 
doubt, be the ideal way of confirming some of the results that I have obtained. Future 
studies looking at the numbers and activity of memory B-cells may also prove to be more 
informative. 
It cannot be forgotten, also, that this is a study that has looked only at „one side of the 
coin‟. Evaluating the levels of antibodies in these women has given us an idea of how im-
munity is being developed, but it fails to show us how the immune cells (particularly 
monocytes and macrophages) of these women are responding to these antibody levels. It 
is possible that women that have shown high phagocytic antibodies levels but no protec-
tion from PM may have impaired monocytic function. It would be extremely interesting to 
measure the function of these cells in pregnant women and correlate this with their anti-
body levels and PM status. 
In conclusion, this work indicates that the measurement of functional antibody is superior 
to the common measurement of total IgG to CS2VSA, (which has been the “gold-standard” 
assay for immunity acquisition in the field of malaria in pregnancy).  
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5.1. Summary 
It was clear from the studies conducted on PG and SG (refer to chapter 4) that there was 
a significant number of serum samples that were able to induce phagocytosis in associa-
tion with extremely low levels of total IgG to VARCSA. This, together with the knowledge 
that Thp-1 cells also express the FcR for IgE, prompted me to investigate whether PG, 
particularly the ones who had very low levels of Total IgG to VARCSA could have levels of 
IgE that would correlate with the observed phagocytosis measured. 
5.2. Literature Review  
5.2.1.  Finding and describing IgE  
Of all the immunoglobulin (Ig) classes known to exist in humans, IgE was the last to be 
discovered with its existence, and acceptance as a distinct Ig, coming in 1966-69 [1]. Be-
fore this, experiments by Prausnitz and Kustner in 1921 had proved the existence of a se-
rum factor that could passively be transferred from an allergic patient to a non-allergic pa-
tient and cause, in the latter, an allergic reaction once the appropriate antigen was admin-
istered, thus providing us with the first demonstration of the biological activity of IgE [1]. 
 IgE is the least abundant of all the Ig classes. This Ig exists as a monomer and has a 
short half-life, of about 3 days, in the serum, compared to the 21 days attributed to IgG [2]. 
Most IgE is sequestered in the tissues associated with immune cells like mast-cells [3]. 
Despite the sequestration of IgE in the tissues (e.g. skin, lung or bowel), and its low con-
centration in serum (approximately 150 µg/mL compared to 10mg/mL for IgG), it can be 
extremely elevated in reaction to parasitic infections or allergens [4] and the increased 
level of IgE in the serum is accompanied by an increase in the number of circulating 
plasma cells that produce it [5], suggesting IgE may have an important role in immunity. 
However, the role of IgE as an immune mediator is mostly recognised in allergies (includ-
ing asthma [6] and food allergies [7], for example) and in response to helminthic infections 
like Schistosomiasis [8]. Its role during a malaria infection, if any, is still not completely re-
solved (see IgE and Malaria below). 
5.2.2.  The IgE receptors 
As was briefly reviewed in Chapter 3 of this thesis, there are three known receptors for 
IgE: FcεRI , FcεRII (CD23) [2] and the recently identified Galactin-3 [9, 10].  
5.2.2.1. FcεRI 
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The FcεRI high-affinity receptor is found on mast cells and basophils in which it induces 
their degranulation [2]. It can also be found on Langerhans cells and mono-
cytes/macrophages [11-14]. This receptor is composed of four chains in both mast cells 
and basophils, but only of three chains in monocytes/macrophages [15]. 
5.2.2.2. FcεRII (CD23) 
FcεRII (CD23) was identified as a receptor for IgE in the early 1990‟s [16, 17]. This recep-
tor is not a member of the immunoglobulin family, unlike all the Fcγ receptors and also 
FcεRI, rather belonging to the C-type lectin receptors [18]. This receptor, although consid-
ered the low-affinity receptor for IgE, is still capable of binding IgE with as much strength 
as CD64, the high-affinity receptor for IgG, binds to its ligand [2]. Found on several types 
of cells including B-cells, monocytes/macrophages, eosinophils and follicular dendritic 
cells, CD23 has two-forms: CD23a and CD23b which mediate either endocytosis and B-
cell stimulation (CD23a) or phagocytosis (CD23b) [19]. 
5.2.2.3. Galectin-3 
The last IgE receptor to be identified, galectin-3 is a beta-galactoside-binding lectin [9, 10] 
found to be expressed on neutrophils (where it plays a role in their activation) [20] and in 
placental trophoblasts [21]. 
5.2.3.  IgE and phagocytosis 
After the discovery of IgE receptors on the surface of human macrophages/monocytes 
[12, 13] the capacity that IgE and its associated receptors could have to induce the 
phagocytic function of mononuclear phagocytes was shown by Boltz-Niculescu et al [22]. 
Using IgE-sensitised sheep RBC, they were able to show that human-donor derived 
monocytes were able to ingest these particles and thus establish the presence and func-
tion of IgE-receptors on the surface of those cells. The receptors responsible for the 
phagocytic activity were still not identified at this stage. This was done a few years later 
after CD23 was identified as one of the receptors for IgE [16, 17]. It was shown, by Yokota 
et al [19] that CD23 (FcεRII) had two variants: FcεRIIa and FcεRIIb. By using stable trans-
fectants expressing the wild-type or mutated forms of these receptors, they were able to 
demonstrate that FcεRIIb was the variant of CD23 responsible for the phagocytosis activ-
ity of IgE while FcεRIIa had a role in endocytic processes. The role of IgE as a mediator of 
phagocytosis has been since elegantly shown in a series of papers from Hannah J. 
Gould‟s lab, where after designing IgE antibodies against Folate Binding Protein (a marker 
of ovarian cancer), they were able to reveal the roles that both IgE and CD23 play in the 
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induction of phagocytosis of cancerous cells by monocytes. This induction of phagocytosis 
is enhanced when in the presence of the cytokine IL-4 [23-25].  
5.2.3.1. IgE receptors and Thp-1 cells 
The presence of receptors for IgE on the surface of Thp-1 cells was first demonstrated in 
a couple of papers where the effect of exposure of various monocytic cell lines to either 
IL-4 or IL-6 and the subsequent increase in expression of CD23 was investigated [26, 27]. 
These studies, together with later ones, established the presence of CD23 on the surface 
of Thp-1 cells. It is important to notice that these studies were conducted with uThp-1 
cells.  
Agents such as Tumour Necrosis Factor-alpha (TNF-α), Interferon-gamma (IFN-γ) and 1 
alpha,25-dihydroxyvitamin D3 (Vitamin D3) were shown to either increase (TNF-α, IFN-γ) 
or decrease (Vitamin D3) the expression of this receptor on the surface of uThp-1 cells, in 
a pattern that closely resembled the one obtained with blood-derived monocytes [28, 29]. 
5.2.4.  IgE and Malaria  
The search for the significance of IgE during a malaria infection, if any, has been marked 
by contradictory results and more doubts and questions than answers, and remains, even 
after 40 years of studies, largely an unknown. 
5.2.4.1. IgE levels 
The first studies that looked at IgE and malaria, relied on the observation that Nigerian 
patients seemed to have much higher levels of IgE in their serum than did Swiss nation-
als, which prompted the question: could malaria be responsible for this increase? The re-
sults of their studies seemed to point to malaria not being associated with an increase of 
the total levels of IgE in the serum of those patients [30]. Desowitz was the first to investi-
gate the presence of Plasmodium-specific IgE in serum samples from residents of malaria 
endemic areas finding that 33% of adults tested revealed IgE to Plasmodium falciparum 
antigens by ELISA [31]. After these initial studies, several others have reported on the 
levels of IgE in malaria patients. The levels of total IgE were reported to be elevated in the 
sera of patients from malaria endemic regions of Africa and Asia and specific IgE to Plas-
modium antigens was verified using both ELISA and protein immunoblotting (Western 
Blots) [32] and these correlated with malaria parasitaemia or malaria attacks [33-37]. 
There are some reports, though, of increased levels of IgE (specific for P. falciparum) as-
sociated with a decrease in parasitaemia [38].  
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5.2.4.2. IgE: protective or detrimental?  
The question of whether IgE levels (total or parasite-specific) are protective or detrimental 
may be a difficult one to answer.  
The first reports on the effect that IgE might have on the outcome of a malarial infection 
presented evidence of an increase in IgE levels in children that presented with cerebral 
malaria when compared with patients that had uncomplicated disease [32]. A higher level 
of IgE was also observed in Thai patients with severe malaria when compared with those 
that presented uncomplicated malaria [33]. In a study conducted in Burkina Faso, children 
with severe malaria had a significant increase of IgE levels in the serum than those with 
non-severe disease and, in the Ivory Coast, children that presented severe malaria also 
had higher levels of IgE [35]. 
On the other hand, in a holoendemic region of Tanzania, and when looking at a population 
of asymptomatic individuals followed longitudinally, high levels of P. falciparum specific 
IgE were associated with a reduced risk of acute malaria, independently of the age group 
[39]. Farouk et al, when studying two ethnic groups in Mali exposed to the same environ-
ment, showed that protection from parasitaemia was associated with higher levels of anti-
malarial IgG and IgE [40]. 
5.2.4.3. Beyond IgE: IL-4 and TNF-α 
Perlmann et al‟s observation that IgG4 seemed to be present in most serum samples 
where IgE against malaria antigens was evident, led them to hypothesise that this might 
be an IL-4 mediated mechanism [32]. Studies conducted using animal models of malaria 
seemed to show that IL-4 had a role in the induction of IgE, but was not absolutely neces-
sary [41]. In human populations living in P. falciparum endemic areas individuals with an 
IL-4/IFN-γ ratio higher than 1 (which would presumably reflect a more Th2 oriented im-
mune response) had higher levels of anti-malarial IgE than did individuals where that ratio 
was lower than 1. This association, although a weak one, was further pursued and it was 
shown that an allelic variant of the IL-4 promoter region (IL4-589T) associated with higher 
levels of IgE in children with severe malaria [42] and, together with another polymorphism 
in the IL-4 promoter region IL4+33, associated with higher IgE levels in cerebral malaria 
victims [43]. The associations were not always towards IL-4 and IgE being detrimental, as 
was shown by the study of Farouk et al that linked IL-4 producing cells and IgE to protec-
tion from malaria [40] and that observed, once again, the IL4-589T could be linked to this 
[44]. 
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TNF-α was found to be secreted by monocytes exposed to IgE-complexes, through the 
action of CD23, and since its release in the capillaries has been associated with tissue 
lesions, it is believed to form part of the process by which IgE might mediate the severity 
of the disease [45]. 
5.2.4.4. IgE, malaria and helminth infections 
Helminths are eukaryotic worm-like parasites that live inside their host [46]. The study of 
the possible interactions between helminthic parasites and Plasmodium sp is a vast field 
and extremely interesting. The main points of these possible interactions are presented, 
but by no means exhaustively. Extremely thorough and informative reviews on the subject 
have been published both on helminths alone [46, 47] as well as on malaria and helminth 
interactions [48, 49]. 
Murray et al showed in the late 1970‟s that, when African populations were treated against 
Ascaris lumbricoides, there was an increase in the risk of recrudescent malaria attacks 
which led investigators to conclude that the immunological milieu created by the worms 
was protecting the host from clinical malaria [50, 51]. This was also the case in a series of 
studies conducted in Thailand where the burden of infection with that same worm, Ascaris 
lumbricoides, was associated with protection from cerebral malaria, independently of the 
nutritional status of the host [52, 53]. More recent studies though have not provided such 
results, rather showing that worm infections might worsen the malaria outcome of those 
that have co-infections [54, 55]. All the results obtained in these studies may be depend-
ent on factors like the host age (the studies in Thailand were performed in adults, the 
studies in Africa are mainly done in children), setting (hospital based or community 
based), helminth species present, malaria species present and even the study type (inter-
ventional, observational, cross-sectional, longitudinal, etc).  
During pregnancy it is believed that worm and plasmodium co-infections lead to exacer-
bated anaemia and even to low birth weight babies especially in PG where co-infection is 
highly prevalent [56, 57]. It is well established that helminthic infections induce a strong 
Th-2 oriented immune response, with an emphasis on the production of IL-4, IL-5 and IL-
13 that drives B-cells to the Ig class switching necessary for the production of IgE [46, 47]. 
CD23, the IgE low-affinity receptor, has been implicated in the interaction between 
helminths and malaria in cerebral malaria [58] nevertheless, in terms of MiP there are, at 
present, no studies that have addressed the presence of IgE and co-infection with 
helminth parasites and Plasmodium spp.  
5.2.5.  IgE during MiP 
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Not many studies have addressed questions related to the role of IgE during MiP and, as 
of the time of writing of this thesis, the role of IgE during a normal pregnancy is also an 
unknown [59]. 
The first studies that investigated IgE (Total and Plasmodium-specific) during MiP were 
conducted by Desowitz et al in Papua New Guinea and were mainly concerned with the 
role that plasmodium-specific foetally generated IgE (stimulated by antigens transferred 
from the mother‟s circulation) could play [60, 61]. As well as cord blood responses, some 
pregnant women were also found to have Plasmodium-specific IgE, and this was more 
common with increasing parity. It is curious that in these studies, plasmodium-specific IgE 
(as measured by ELISA) was not able to be detected in PG. Deposition of IgE in the pla-
centas of infected women (from both Malawi and Papua New Guinea) was demonstrated 
by Maeno et al and a possible negative association with the degree of parasitaemia was 
found[62]. Deloron et al also were able to detect plasmodium-specific IgE in maternal se-
rum from Cameroonian pregnant women but failed to detect any possible association or 
role for these IgE with malaria infection [63]. The last study that has focused on maternal 
IgE and MiP was conducted by Rindsjo et al, where the presence of IgE associated with 
cells in the placenta was evaluated immunohistochemically. IgE was found to be mainly 
associated with Hofbauer-like cells, macrophage-like cells resident in the placenta, and no 
differences in the pattern of expression of IgE, between placentas of Ghanaian women 
with or without evidence of malaria parasites were reported. There was also no correlation 
between the levels of IgE in the maternal serum and the presence of these IgE+ cells [64]. 
5.2.6.  IgE and PG: why investigate? 
The few studies that have focused on MiP and IgE [60-64] have failed to give us a clear 
idea of the role that IgE might play in the development or outcome of the disease. Besides 
being mainly focused at detecting the presence or absence of IgE in pregnant women and 
trying to relate that presence/absence with the presence of malaria parasites, not much 
more has been answered.  
What are the levels of IgE at the beginning and end of pregnancy? How do they relate to 
IgG? Are IgE levels associated with helminth infections during pregnancy? How do the 
different helminth infections affect the levels of malaria-specific IgE and how are they re-
lated to the outcomes of MiP? Does IPTp treatment influence the levels of IgE in pregnant 
women?  
There are a number of questions left to answer and especially important may be the ques-
tions that concern PG. Do PG, with no IgG to the MiP-like malaria parasites have, at the 
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beginning of pregnancy, IgE that recognises the parasite? If so, where does that IgE come 
from? Is it cross-reacting? Are PG that exhibit higher levels of these IgE more or less pro-
tected from MiP? What is the pathway by which these IgE work? Do they induce ADCC 
responses in the placenta that might correlate with increased levels of inflammatory cyto-
kines? Do they work as anti-adhesion antibodies, or are they a first line of antibodies that 
might contribute to the clearance of parasites by phagocytosis? Since it seems clear that 
placental trophoblasts express galectin-3, what could the presence of IgE-covered Plas-
modium pRBC mean in terms of pregnancy outcome? 
There are too many questions unanswered, and this thesis does not aim to answer them 
all, but my results, as described in Chapter 4, led me to hypothesize that, in PG that ex-
hibit low levels of total IgG to CS2VSA but still elicited good levels of phagocytosis, para-
site-specific IgE could be playing the role of opsonising antibodies.  
5.3. Methods 
The results pertaining to the function of IgG towards CS2VSA and total IgG to CS2VSA 
phagocytosis assay were obtained during the work described in Chapter 4 and the meth-
ods are described in detail in Chapter 4, section 3. 
I would like to thank Sara Prickett for providing me with some anti-IgE antibodies used in 
the preliminary stages of this study and Michael Duffy and Michaela Peter for providing 
me with the anti-ATS antibodies. 
I would like to thank Elizabeth Aitken for providing me with her unpublished protocols for 
the detection of parasite-specific IgE by ELISA. 
5.3.1.  Ethics statement  
The work presented in this chapter used samples from the MHP study cohort conducted in 
Blantyre, Malawi, which got its ethical clearance from the College of Medical Research 
and Ethics Committee, University of Malawi and the Melbourne Health Human Research 
Ethics Committee. 
5.3.2.  Western Blotting 
This protocol is an adaptation of methods previously published [65, 66]. Twenty samples 
of serum that had low total IgG to CS2VSA were used. 
5.3.2.1.  Solutions used 
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Protease inhibitors: 1 tablet Cocktail tablet Complete-Mini (Roche) in 10 mL PBS 
1% Tx-100: 1mL Triton-X 100 (Sigma-Aldrich, St Louis, Missouri) in 99mL PBS 
2%-SDS: 2g Sodium Dodecyl Sulphate (SDS) in 90 mL PBS. This was heated to 68°C 
and stirred. The pH was then adjusted to 7.2 with HCL 1M and the volume adjusted to 
100mL. 
1x Tris-Acetate (TA) Running Buffer: 100 mL of Tris-Acetate 10x in 900 mL of MilliQ water 
1x Tris-Glycine Transfer Buffer: 100 mL Tris-Glycine 10x (with 0.1% SDS), 200 mL 
Methanol in 700 mL MilliQ water., kept ice-cold until use. 
10x Tris Buffer Saline – Tween (TBS-T): 30g Tris, 45g NaCl, 5 mL neat Tween20, 495 mL 
H2O.   
Blocking Solution: 50 mL TBS-T 10x. Add 300 mL H2O and 50 g Skinned Milk (powder), 
stirred for 10 min, adjusted to a final volume to 500 mL and filtered. 
TBS-T with Milk (TTM): 1/2 dilution of Blocking Solution in TBS-T 
TTM-High salt: TTM + 2g per 100 mL of NaCl 
5.3.2.2. Preparation of protein extract 
A CS2-GFP parasite culture, of > 5% trophozoites was collected and spun for 5 min at 
400 rpm. The pellet was resuspended in 2mL of RPMI-HEPES and the trophozoites were 
purified by Percoll and counted. Briefly, parasite cultures were overlaid on a gradient of 
80%, 60% and 40% Percoll (Amersham) in RPMI-HEPES. After centrifugation at 2,000g x 
15 min, cells resting on the 60% layer were collected and washed thrice at RT with RPMI-
HEPES (400g for 5 min). After counting, a final spin was performed and the supernatant 
was discarded. From here on after, all the procedures were done on ice. The parasite pel-
let was lysed with the help of 1% Triton-X 100 in PBS containing protease inhibitors (TX-
100PI) and spun at high speed at 4°C for 10 min. The supernatant was discarded and the 
pellet washed in 1 mL of TX-100PI and re-spun at high speed at 4°C for 10 min. The pellet 
was then resuspended vigorously in 2% SDS in PBS at a ratio of 108 parasites/mL (800 
µL). The solution was then spun at high speed (just long enough to bring the pellet down), 
and the pellet resuspended again until no more pellet was able to be dissolved. The solu-
tion was then spun at high speed for 10 min and the supernatant collected. 
5.3.2.3.  Running of the protein extract on a gel 
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A 3-8% Tris-Acetate gel with only one sample well and a control well (NuPAGE, pre-cast 
gels, Invitrogen) was mounted on a small gel apparatus filled with TA-running buffer, mak-
ing sure that the well of the gel was filled with the buffer. One-hundred microliters of the 
protein extract preparation (containing 490µg/mL of protein) was added to 100 µL of sam-
ple buffer (4% SDS, 10% ME, 20% Glycerol, 0.004% bromophenol blue, 0.125M Tris-HCl 
pH 6.8) and this mix was vortexed and boiled for 3 min in a heating block. This was done 
to reduce and denature the proteins. The 200 µL of sample were then applied to the sam-
ple well of the gel and 5 µL of pre-stained protein molecular weight marker (max of 210 
kD) (Invitrogen) was used in the control well. The sample was then run for 10 min at 90 
volts and then for 45 min (or until the migration front exited the gel) at 180 volts. A protein 
ladder (SeeBlue®Plus2 pre-stained standard, Invitrogen) was used to determine the mo-
lecular weight of the protein bands. 
5.3.2.4.  Transfer of the protein bands to nitrocellulose membranes 
Fifteen minutes before beginning the transfer, an ice block and the transfer buffer were 
put at -80°C. The gel was cast off its support and „sandwiched‟ between one sponge pad, 
two pieces of Whatman blotting paper, and one nitrocellulose membrane, two pieces of 
Whatman blotting paper and a sponge pad. The transfer of the protein bands to the nitro-
cellulose membrane was achieved by electrophoresis in transfer buffer with agitation and 
in the presence of a frozen ice block for one hour at 100v. 
5.3.2.5.  Blocking, probing and developing the membrane 
The membrane was marked with a line on top and bottom and then cut into fine strips ap-
proximately five millimetres wide. Each strip was numbered. The strips were then incu-
bated with blocking solution with agitation for 2.30 hours.  
Probing of the strips was done for one hour with one mL final volume of serum or antibod-
ies diluted in TTM. The dilutions used were 1:2000 dilutions of serum for IgG and 1:25 di-
lutions of serum for IgE. Two pools of serum samples that had low total IgG to CS2VSA and 
either high (HP) or low (LP) phagocytosis values towards CS2VSA were used. Control anti-
bodies used were a 1:200 dilution of an anti-ATS (Acidic Terminal Sequence) 2747/affinity 
purified antibody [65] (recognises in CS2 parasites a single band corresponding to the lo-
calization of PfEMP-1), 1:200 dilution of anti-ATS 3031/rabbit serum (recognises 2 bands, 
at least one of which should be PfEMP-1 and the other one may be a RBC membrane 
component), a 1:10,000 dilution of RaH (the same antibody used as a control during the 
phagocytosis assays). After 1h incubation, the strips were washed 1x5min with TBS-T, 
1x5min with TTM-high-salt and 1x5min with TTM (Wash). A 1h incubation followed with 
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rabbit anti-human IgE antibody (DAKO, ref: A0094) used at a dilution of 1:1,000 for the 
detection of human IgE, or with a 1:500 dilution of rabbit antihuman IgG antibody (Dako-
Cytomation, Denmark) for the detection of IgG. A new wash was performed and a final 1h 
incubation, this time with a 1:2,000 dilution of (WHAT?) anti-rabbit coupled with horse-
radish peroxidase (HRP) (Invitrogen). A new wash was performed. Finally, equal volumes 
of reagent A and reagent B from ECL kit (GE Healthcare) were mixed and added to the 
strips for 1 min. The strips were then gently taken out of the ECL and aligned on transpar-
ent sheets, before being put on Hypercassette (Amersham Biosciences) and revealed in 
an Agfa 1000 developer. 
5.3.3.  IgE measurement by ELISA 
For the measurement of IgE by ELISA, the original serum samples (not heat-inactivated) 
of the PG cohort were used. A total of 115 samples were analysed corresponding to all 
the PG samples that had a total IgG to CS2VSA level of less than 3% of positive control. 
5.3.3.1. Total IgE 
Total IgE was measured using a sandwich ELISA. In brief a mouse anti-human IgE mono-
clonal Ab 107 (MABTECH) 2ug/mL in PBS 100μl/well, was left to adhere to Nunc Max-
iSorp™ flat bottom 96 well plates (Nunc, Thermo Fisher Scientific, Roskilde, US) over-
night at 4°C. The plates were then washed thrice with wash buffer (PBS 0.1% Tween20) 
and blocked (100µl/well blocking solution-PBS 0.1% Tween20 with 10% Skim milk) for 1 
hour at room temperature (RT) followed by three washes with wash buffer and incubated 
with 100µl/well samples diluted 1/1000 in reagent diluent (PBS 0.1% Tween20 with 5% 
Skim milk) or purified IgE standards (MABTECH) 0-40ng/mL (8 points) for two hours at 
RT. The plates were then washed thrice and incubated with 100µl/well of biotinylated 
Mouse anti-human IgE monoclonal antibody 182 0.5ug/mL in reagent diluent for 1 hour at 
RT, after which plates were washed thrice and 100µl/well streptavidin-HRP conjugated 
antibody (P0397 from DAKO, Denmark) diluted 1/300 in reagent diluent and incubated on 
the plate for 1 hour at RT. The plate was washed thrice with wash buffer and 100ul/well of 
HRP substrate made as described by manufacturer from ECL substrate kit (Amersham) 
for 5 minutes until colour developed, reaction was stopped with the addition of 50 µl/well 
1N HCl solution. The plate was read at 490 nm. 
5.3.3.2. Antigen-specific IgE 
P. falciparum IgE was measured after using an indirect ELISA to overcome the problem of 
IgG competing out IgE binding of antigen (unpublished protocol provided by Elizabeth Ait-
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ken). In brief a mouse anti-human IgE monoclonal (Ab 107,MABTECH), 2ug/mL in PBS 
100ul/well, was incubated overnight at 4°C in Nunc MaxiSorp™ flat bottom 96 well plates 
(Nunc, Thermo Fisher Scientific, Roskilde, US). The plates were then washed thrice with 
wash buffer and blocked for 1 hour at RT, followed by three washes with wash buffer and 
incubated with 100µl/well of samples or controls, diluted 1/50 in reagent diluent for 2 hours 
at RT. The plates were then washed thrice and incubated with schizont extract (1/300) at 
RT for 2h. The plates were then washed thrice and 100µl/well of hyperimmune sera (pps 
sera, also used in the phagocytosis assays as positive control) diluted 1/1000 was added 
to each well and left for 2 hours at RT, following which the plates were washed thrice and 
100µl/well Goat anti-human IgG–HRP (GAH, Silenius Labs) 1/5,000 in reagent diluent for 
1 hour. The plates were then washed thrice and 100µl/well HRP substrate made as de-
scribed by manufacturer from ECL substrate kit (Amersham) for 10 minutes until colour 
developed. The reaction was stopped with the addition of 50 µl/well 1N HCl solution. The 
plate was read at 490 nm. 
5.3.3.3. Analysis of results 
Total IgE was calculated as µg/mL using the standard curve. 
The values for IgE to the CS2 Plasmodium falciparum extract were standardised and ex-
pressed relative to controls (mean of non-exposed controls 0, mean of pps, 100) as rela-
tive absorbance in arbitrary units.  
5.4.  Results 
5.4.1.  Choosing the samples for IgE measurement. 
As was seen for the PG and SG cohorts on chapter 4 (section 4.2.2 and section 4.3.2), a 
percentage of women in whom the levels of total IgG to CS2VSA were very low had high or 
relatively high values for phagocytic function. Adding to this, PG had a lower degree of 
correlation than SG between the two antibodies‟ parameters measured (Figure 5-1). Fo-
cusing on the PG samples, where IgG had the worst correlation between total and func-
tional levels, I decided to study the group of samples that had less than 3% total IgG to 
CS2VSA (median value for all the samples of PG excluding all the samples for which total 
IgG was zero) (Figure 5-2). 
5.4.2.  Western blot analysis: IgE associates with higher values of phagocytosis 
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Samples chosen for the detection of IgE were derived from the same aliquots used in 
Chapter 4. These were pooled into two groups according to the levels of phagocytosis ob-
tained. Samples were grouped as having high phagocytosis (HP, n=20) values if phago-
cytic function was > 10% and as having low phagocytosis if phagocytic function was <10% 
(LP, n=21). A pool of male serum, taken from fathers of children admitted to the same 
hospital (Queen Elizabeth Hospital, Blantyre, Malawi) where the PG samples were taken, 
and a pool of serum from Melbourne donors were used as controls. 
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Figure 5-1 – Correlation between total IgG to CS2VSA and phagocytic function for PG and SG 
Both PG (circles) and SG (triangles) values for total IgG to CS2VSA and phagocytic function are plotted. Linear 
regression lines (full line – PG, broken line – SG) and r
2
 values are shown. 
 
Figure 5-2 – Plot of total IgG to CS2VSA and phagocytic function in primigravidae with cut-off for IgE 
studies. 
Plot of the cut-off line used for the selection of samples to be used on IgE studies. Dotted line at 3% of total 
IgG to CS2VSA was determined by calculating the median of the values for total IgG to CS2VSA for all PG sam-
ples with the exception of those to which the value was zero.  
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5.4.2.1.  Western blots reveal protein bands to which IgE associates in the 
group with increased levels of phagocytic function 
Protein extracts from the parasite line Plasmodium falciparum CS2-GFP were separated 
on a 3-8% Tris-Acetate gel and probed with serum samples that demonstrated to have 
low total IgG to CS2VSA (<3%). These were divided into two pools, a pool with low phago-
cytosis function (<10%, LP) and a pool showing high phagocytosis function (>10%). Pools 
of male serum, Melbourne donor control serum and CS2 positive serum were used as 
controls. An affinity purified anti-ATS antibody was used to detect PfEMP-1 as well as 
rabbit-sera against the ATS of PfEMP-1. 
As can be seen in Figure 5-3, the anti-ATS control antibody recognised a single high-
molecular weight (~300kD) protein band corresponding to the molecular weight of PfEMP-
1 of Plasmodium falciparum CS2 (strip 10), while the rabbit-sera against the ATS of 
PfEMP-1 recognised not only a similar band corresponding to PfEMP-1 but also a band 
corresponding to a probable RBC derived protein (strip 9) that is also recognised by the 
rabbit anti-human RBC antibody used in phagocytosis assays (strip 1), as well as by all 
the strips probed with human serum (2-8). At the dilutions and exposure time used, no 
protein bands exclusive to the strips probed with human were found. After exposing the 
films to the strips for one minute (Figure 5-4) it was possible to visualise a number of pro-
tein bands that are equally recognised by all strips as well as 2 possible protein bands 
(strips 6 and 7, white asterisks) of molecular weight between 111 and 71 kD. 
To confirm the presence of the protein bands associated with the HP pool of sera, new 
membranes were prepared and probed with HP serum, LP serum and affinity purified anti-
ATS antibody. As can be seen in Figure 5-5, at a dilution of 1:25, and after 20s exposure 
there are clearly two protein bands of molecular weight between 111 and 71 kD that are 
recognised by IgE in the HP group but that are absent in the LP group. These protein 
bands do not correspond to PfEMP-1. 
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Figure 5-3 – Western blot of CS2-GFP membrane proteins probed with Primigravidae serum, 20 sec-
onds exposure. 
Membrane associated proteins were extracted from Plasmodium falciparum CS2-GFP parasites and sepa-
rated on a 3-8% Tris-Acetate gel. These were then transferred to a nitrocellulose membrane and probed with 
human serum (strips number 2-8) or control rabbit antibodies (strips number 1, 9 and 10). A Rabbit anti-
human IgE antibody was used to detect any IgE associated with the proteins on membrane strips 2-8. Film 
was exposed to the strips for 20 second (after incubation with a horse-radish peroxidase coupled antibody and 
ECL substrate). Numbers to the left represent the position and molecular weight (kD) of the standard (See-
Blue®Plus2 pre-stained standard, Invitrogen).  
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Figure 5-4 - Western blot of CS2-GFP membrane proteins probed with Primigravidae serum, 60 sec-
onds exposure. 
Membrane associated proteins were extracted from Plasmodium falciparum CS2-GFP parasites and sepa-
rated on a 3-8% Tris-Acetate gel. These were then transferred to a nitrocellulose membrane and probed with 
human serum (strips number 2-8) or control rabbit antibodies (strips number 1, 9 and 10). A Rabbit anti-
human IgE antibody was used to detect any IgE associated with the proteins on membrane strips 2-8. Film 
was exposed to the strips for 20 second (after incubation with a horse-radish peroxidase coupled antibody and 
ECL substrate). White asterisks represent 2 putative protein bands to which IgE seems to be associated in the 
HP group of pooled serum. Numbers to the left represent the position and molecular weight (kD) of the stan-
dard (SeeBlue®Plus2 pre-stained standard, Invitrogen). 
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Figure 5-5 – Confirmation western blot of CS2-GFP membrane proteins probed with Primigravidae se-
rum, 20 seconds exposure. 
Membrane associated proteins were extracted from Plasmodium falciparum CS2-GFP parasites and sepa-
rated on a 3-8% Tris-Acetate gel. These were then transferred to a nitrocellulose membrane and probed with 
two pools of human serum (Low: Low phagocytosis pool; High: High phagocytosis pool) or with a control af-
finity purified rabbit anti-ATS antibody (ATS). A Rabbit anti-human IgE antibody was used to detect any IgE 
associated with the proteins in the HP and LP strips. Film was exposed to the strips for 20 second (after incu-
bation with a horse-radish peroxidase coupled antibody and ECL substrate). Red box represents the location 
of the two putative protein bands recognised by IgE in the high group but not in the low group. (M) Molecular 
marker, represents the position and molecular weight (kD) of the standard (SeeBlue®Plus2 pre-stained stan-
dard, Invitrogen). 
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5.4.2.2.  Levels of IgE detected on western blots are not dependent on mater-
nal age or on levels of total IgG to CS2VSA 
Due to the dependence of IgE on age, the maternal age of both the HP and LP groups 
were compared using student‟s t Tests. No significant differences were detected between 
both groups (P=0.299), excluding age as an influencing factor (Figure 5-6A). The levels of 
total IgG to CS2VSA were also assessed between both the LP and HP groups, using Mann-
Whitney ranksum tests. The LP group revealed to have higher values of total IgG to 
CS2VSA than the HP group (P=0.03) (Figure 5-6B). 
5.4.3.  Evaluation of IgE levels by ELISA 
The levels of both total and antigen specific IgE present in the sera of PG that had less 
than 3% of total IgG to CS2VSA were evaluated by ELISA (n=115). The results were then 
introduced in the database used for the analysis of the results shown in Chapter 4 and 
analysed for association of IgE with IgG parameters measured and HIV status of the 
women. 
5.4.3.1.  Distribution and correlation of total IgE and antigen specific IgE in the 
primigravidae cohort. 
The median level of total IgE present in this group of PG was 763, 285-5358 µg/mL (me-
dian, 95% CI) while the distribution of antigen-specific IgE was (in relative, arbitrary units) 
53.01, 18.2-140.6 (Figure 5-7A). 
There was no correlation between the levels of total IgE and antigen-specific IgE in this 
group of PG (Figure 5-7B). Spearman‟s rank correlation yielded a P-value of 0.835, with a 
rho of -0.02 while linear regression failed also to show any association (r2=0.0009, 
P=0.756). 
5.4.3.2.  Associations between levels of IgE measured and IgG, maternal age 
and HIV. 
The levels of both total IgE and antigen-specific IgE were analysed with regards to the 
possible associations with total IgG to CS2VSA, phagocytic antibodies‟ function, maternal 
age and HIV status (Table 5-1). Univariate linear regression methods, revealed a lack of 
association between the levels of total IgE and any of the other antibodies‟ measurements 
obtained for this group of PG.  
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Figure 5-6 – Maternal age and Total IgG to CS2VSA distribution among the two pools of primigravidae 
serum used in Western Blot 
A) The two groups of women (LP-low phagocytosis, HP- high phagocytosis) included in the pools of PG serum 
used to probe nitrocellulose membranes containing membrane antigens of Plasmodium falciparum CS2 para-
sites were found to have no difference in maternal age (Student‟s t-test: P=0.296). B) The levels of total IgG to 
CS2VSA were found to be higher in the LP group than in the HP group, reaching statistical significance (Mann-
whitney ranksum: P=0.03). n.s. (non-significant). Total IgG to CS2VSA is given as a percentage of positive con-
trol. 
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Figure 5-7 – Distribution and correlation of total and antigen specific IgE in the cohort of primigravidae 
with low total IgG to CS2VSA levels 
(A) Dot plots representing the distribution of total IgE (open squares) and antigen –specific IgE (filled circles). 
The median lines are plotted. (B) Correlation between total IgE and antigen-specific IgE. The linear regression 
curve and 95% confidence intervals are plotted. Values for both the P-value and the r
2
-value are also shown.  
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Levels of antigen-specific IgE failed to show any association with the total amount of IgG 
to CS2VSA but showed a significant association with the function of phagocytic antibodies 
(coeff: 0.874, P=0.002). Maternal age showed an association with the levels of total IgE 
(coeff: -113.90, P=0.017) but not with the levels of antigen-specific IgE. 
Total IgE levels did not seem to be influenced by the presence of an HIV infection (Mann-
Whitney ranksum: z=1.26, P=0.209, Figure 5-8A) but antigen-specific IgE was significantly 
increased in HIV positive PG compared to HIV negative PG (Mann-Whitney ranksum: 
z=4.48, P<0.001, Figure 5-8B). In contrast, evidence of placental malaria (PM) was asso-
ciated with lower levels of antigen-specific IgE (Mann-Whitney ranksum: z=2.06, P=0.04, 
Figure 5-8D). No association was found between total levels of IgE and evidence of PM 
(Mann-Whitney ranksum: z= 0.19, P=0.848, Figure 5-8C). 
5.4.3.3.  After multilinear regression analysis, antigen-specific IgE is associ-
ated with phagocytic antibodies and HIV in primigravidae with low to-
tal IgG to CS2VSA.  
In order to confirm the strength of the associations obtained with the univariate analysis 
conducted, both the total levels of IgE and the levels of antigen-specific IgE were ana-
lysed by multilinear regression analysis against maternal age, phagocytic function, total 
IgG to CS2VSA and HIV status. Since both phagocytic antibodies and total IgG to CS2VSA 
are highly associated to PM status (Chapter 4) multivariate analysis was performed after 
dividing the women into PM positive and PM negative.  
Total IgG to CS2VSA failed to associate with any of the parameters of IgE measured (data 
not shown). Multivariate analysis revealed that antigen-specific IgE retained its associa-
tion to phagocytic antibodies (coeff: 0.74, P=0.005) and HIV status (coeff: 31.45, P=0.001) 
only in PM negative women. Total levels of IgE also remained associated with maternal 
age (Coeff: -136.71, P=0.042) after adjusting for HIV infection and phagocytic antibodies 
(Table 5-2) (results for women with PM yielded no significant results and are not shown). 
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Table 5-1 – Univariate associations between IgE levels, IgG parameters and maternal age 
  Total IgE
1 
[Coef, (P-value), CI]
3 
Antigen-specific IgE
2 
[Coef, P-value, CI] 
Phagocytic antibodies -8.64 (0.516) -34.95, 17.65 0.874 (0.002) 0.33, 1.42 
Total IgG to CS2VSA 184.33 (0.391) -239.65, 608.31 -4.19 (0.371) -13.41, 5.04 
Maternal age (years) -113.90 (0.017), -206.97, -20.82 1.60 (0.129) -0.47, 3.69 
 
 
1
Total IgE in ng/mL 
2 
Antigen-specific IgE is in relative, arbitrary units 
3
 Linear regression coefficients (coeff), P-values and 95% confidence intervals (CI) 
 
 
 
Figure 5-8 – Univariate associations between IgE level, HIV infection and placental malaria status 
The associations between the levels of total IgE (A and C) and antigen-specific IgE (B and D) with HIV and 
Placental malaria were evaluated. Only the antigen-specific IgE associated with HIV status (B) and the placen-
tal malaria status (D). Mann-Whitney ranksum test was performed to evaluate the significance of the associa-
tions. P-values are shown. (n.s.) non significant. 
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Table 5-2 – Multivariate analysis of levels of IgE in placental malaria negative primigravidae 
Variables Total IgE   Antigen-specific IgE  
 Multivariate analysis
1 
Coeff (95% CI) 
P
2
  Multivariate analysis
1 
Coeff (95% CI) 
P 
      
Phagocytic antibodies -9.85 (-39.95, 20.26) 0.516  0.74 (0.23, 1.26) 0.005 
      
HIV infection 306.99 (-680.96, 1294.95) 0.537  31.45 (14.21, 48.70) 0.001 
      
Maternal age (years) -136.71 (-268.35, -5.08) 0.042  1.44 (-0.81, 3.70) 0.206 
      
 
1 
Multilinear regression analysis coefficient (coeff) and 95% confidence intervals (95% CI). 
2 
P-values. A nega-
tive coefficient indicates a negative association and a positive coefficient indicates a positive association 
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5.5. Discussion 
The work presented in this chapter represents a preliminary attempt at answering a ques-
tion that has not been the focus of many research studies: what is the function of IgE dur-
ing a Plasmodium falciparum infection in pregnant women?  
5.5.1.  Total IgG to CS2VSA and phagocytic antibodies do not correlate leaving 
room for another player. 
The observation that there are women whose serum can induce a phagocytic response, 
when used in experimental settings, despite having low levels of the phagocytosis induc-
ing antibody class IgG towards MiP-type pRBC surface antigens, led me to believe that 
other opsonins might have been present in the serum of those women. If so, these opson-
ins would surely be of importance especially in women where the probability of having de-
veloped IgG towards VSACSA was low. If this was in fact true, than the correlation between 
the levels of IgG to VSACSA in PG would have to have a lower correlation coefficient to 
phagocytosis function than the one obtained with more exposed women who had more 
time to develop IgG to VSACSA. This proved to be correct, with SG having a higher correla-
tion coefficient between both total IgG and phagocytic antibodies than PG (Figure 5-1).  
This observation led me to search for the identity of the opsonin responsible. All the serum 
samples used in the phagocytosis assays conducted in Chapter 4 were heat-inactivated, 
which excluded a possible role for Complement. The knowledge that IgE receptors were 
present on the surface of uThp-1 cells [26, 27] and that IgEs (both total IgE and Plasmo-
dium specific IgE) were already found associated to MiP [60, 62, 63, 67], made IgE a can-
didate. Besides, there were no previous studies addressing IgE as a possible phagocyto-
sis enhancer during a Plasmodium infection despite the well known role that this Ig can 
play in phagocytosis [23, 25]. 
Trying to conduct assays similar to the FACS-based total IgG to CS2VSA assays in order to 
detect IgE proved to be extremely difficult and may be dependent on the development of a 
better protocol (results for the FACS based Total IgE to CS2VSA are not shown).  
5.5.2.  Serum used in phagocytosis assays revealed to have IgE associated with 
higher levels of phagocytosis by western blot. 
One impediment for the role that IgE might have had on the phagocytosis results obtained 
in Chapter 4 is the fact that heat inactivation seems to partially degrade IgE [68, 69]. De-
spite this, and since the phagocytosis assay relies on surface antigens of the pRBC, it 
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was decided to conduct the western blots using the exact same aliquots used in Chapter 
4. Protein preparations of membrane associated structures of CS2-GFP Plasmodium fal-
ciparum were made with the use of extraction by Triton-X and solubilisation in SDS .The 
presence of a high molecular band recognised by the anti-ATS antibodies in all the prepa-
rations used assures us that if PfEMP-1 was present, surely other surface-membrane as-
sociated proteins must also have been present and thus available for probing (Figure 5-3).  
By probing the CS2-GFP Plasmodium falciparum protein preparation with male serum and 
Melbourne serum, a possible unspecific role of IgE would be eliminated and the absence 
of specific protein bands associated with these serum pools seems to suggest that (Figure 
5-3 and Figure 5-4). If the case can be argued that Melbourne serum donors may have 
much less IgE when compared to residents of malaria endemic countries, the same can-
not be said for the male serum donors (in fact, early results done in collaboration with 
Sara Prickett, from the Immunology Dept of Monash University, Melbourne, Australia 
showed no differences between the levels of Total IgE in these male donors and in MG 
from the same MHP cohort. Data presented in poster format at the International Confer-
ence for Parasitology, ICOPA, in August 2010, Melbourne, Australia).  
At higher dilutions two protein bands of between 111 and 71 kD seemed visible in the 
membrane strips probed with HP serum but absent in other strips, namely the LP strips 
(Figure 5-4) which was then confirmed by probing new strips with a lower dilution of the 
same serum pools (Figure 5-5). Even if some heat-inactivation may have degraded IgE 
present in those samples, there was still enough present to show that HP samples have 
IgE that recognises two protein bands associated with the membrane of CS2-GFP Plas-
modium falciparum and that the same cannot be said of the LP serum pool. This was not 
due to a difference in the age of the women whose serum was used in the pools (Figure 
5-6A). Some IgG-mediated effect (like the binding of IgG2 or IgG4 to the same epitopes 
recognised by IgE) could be occurring in the LP samples since the LP pool had signifi-
cantly higher levels of total IgG to CS2VSA than the HP pool although the extremely low 
levels of IgG in both groups render this explanation unlikely (Figure 5-6B).  
It was not the goal of this part of the study to identify any of the proteins present in the 
protein bands recognised by IgE. What can be said though is that these are very unlikely 
to be PfEMP-1 or any of the proteins recognised by the polyclonal rabbit anti-human RBC 
antibody used as a control in phagocytosis assays. These proteins, identified by western 
blot as being recognised by IgE should be the focus of future research although it has to 
be taken into account the fact that a process of reduction and denaturing of the proteins 
Chapter 6 2011 
 
161 
 
was conducted in order for them to run in the Tris-Acetate gel, which can expose epitopes 
that are not naturally exposed or even hide epitopes that are usually present. 
5.5.3.  Antigen-specific IgE associates with phagocytosis in the context of HIV 
infection 
The decision to search for IgE, both total and antigen specific, by ELISA was taken with 
the higher throughput of the technique and its higher sensitivity in mind. 
Again, only the PG samples that revealed to have less than 3% of total IgG to CS2VSA 
were used, but this time the original serum samples (not heat-inactivated) were used 
which provided an increased availability of serum samples allowing for 115 samples to be 
processed in duplicate for both total IgE and antigen-specific IgE. The choice of antigen to 
be used (same as on the western blots or a more conformational correct one) fell on the 
commonly used schizont extract, prepared by cycles of freeze and thaw [70].  
Due to the design of the study, with a very limited range of total IgG to CS2VSA on all sam-
ples used, it was not expected that associations of this parameter with any of the IgE 
measured would be found, and that was indeed the case. 
The levels of total IgE and antigen-specific IgE detected in this cohort of PG were not cor-
related with each other. This reduces the possibility that the results obtained for the anti-
gen-specific IgE may be a reflection of a general IgE response by these women.  
Total IgE levels were associated with maternal age, being reduced by 113.90 µg/mL with 
every added year of age (Table 5-1). This was an unexpected result as IgE is usually con-
sidered to increase with age in areas where malaria is endemic [34, 71], although one 
study by Perlman et al seems to show a decrease of IgE occurring after 16 years of age 
[45]. The negative association of total IgE with age still prevailed after adjusting for HIV 
infection and levels of phagocytic antibodies, in PM negative women (Table 5-2). Simi-
larly, in PM negative women, antigen-specific IgE levels were independently associated 
with HIV infection and phagocytic antibodies, after adjusting for maternal age (Table 5-2). 
This is another clue to the possible involvement of IgE as a phagocytic antibody class in 
malaria (something that was vaguely suggested by Khusmith [34]), which may be of par-
ticular relevance in HIV positive women who possess low levels of IgG to fight a Plasmo-
dium falciparum infection during pregnancy.  
5.5.4.  Final discussion, ideas and future work 
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This study was intended to be a platform from which other studies are to be conducted. 
For a complete idea of the role of IgE as a phagocytic antibody class in MiP other, more 
complete, studies should be performed. It will be important to show that IgE are actually 
able to recognise and bind to MiP-type pRBC and that this will in turn induce phagocyto-
sis. This can be achieved, for example, by affinity purifying IgE from pools of serum from 
pregnant women from malaria endemic regions, exposing pRBC to that IgE and conduct-
ing phagocytosis assays. It will also be interesting to show if these IgE are, as I hypothe-
sise, already present at the onset of infection and are thus not MiP-specific, but may be 
cross-reacting IgE. This would open the scene for other players like non-MiP pRBC or 
even (and more likely) helminths, which have been shown to be able to induce high levels 
of IgE and even associate with protection from malaria outcomes [48, 49]. Studies looking 
at the prevalence of helminth infection and levels of IgE at enrolment in PG versus MG 
and their correspondent levels of phagocytic antibodies‟ function against VSACSA express-
ing Plasmodium falciparum parasites would be extremely interesting to perform. Once 
again, and although very speculative at this point, I believe that IgE would prove to be of 
some importance in PG and not MG, where the levels of IgG to VSACSA would no doubt be 
sufficient to “hide” possible IgE-binding epitopes (Figure 5-9). 
The possible effect that IgE complexes, or IgE deposits in the placenta might have is also 
something that is left unanswered, as are the potential roles that cytokines like IL-4 and 
TNF-α might be playing in this model. As I said, this study is a first insight into a field that 
still has a lot to offer. IgE has been extensively studied by malariologists, but it is time to 
stop being satisfied with stating their presence or absence and understand what possible 
functions might be attributed to them, and how a better rationale for the design of strate-
gies to combat malaria can be achieved.  
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Figure 5-9 – Model of how IgE/IgG to VSACSA ratios could differently influence the effect of IgE as an 
opsonin in primigravidae and multigravidae. 
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